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ABSTRACT
Currently, there is no available neuroprotective treatment for reducing acute brain
injury following stroke. Recent studies have demonstrated that poly-arginine and
arginine-rich peptides (e.g. R18; R = arginine residues) exhibit potent neuroprotective
properties in both in vitro and in vivo stroke models, and therefore have the potential
to be developed into a neuroprotective treatment for stroke. Consequently, the aim of
this thesis was to further assess the neuroprotective efficacy of several poly-arginine
and arginine-rich peptides in permanent and transient middle cerebral artery occlusion
(MCAO) stroke models in the rat.
The poly-arginine peptides R12, R15, R18 and the arginine-rich peptide protamine
were assessed in a permanent MCAO model when administered intravenously 30
minutes after stroke onset. Treatment with R12, R18 and protamine significantly
reduced infarct volume in this model. In a subsequent dose response study (100, 300,
1000nmol/kg) with the lead R18 peptide, when administered intravenously 60 minutes
after stroke onset using the permanent MCAO model, infarct volume was reduced by
12 - 24%. Surprisingly, the well characterised neuroprotective peptide TAT-NR2B9c,
clinically known as NA-1, which was used as a positive control did not exhibit any
significant neuroprotection.

When examining R18 efficacy in a milder transient/reperfusion 90-minute MCAO
stroke model, the peptide provided significant neuroprotection. R18 decreased infarct
volume by 24 and 35% when administered intravenously 60 minutes post-occlusion at
the 300 and 1000nmol/kg doses. In comparison, NA-1 decreased infarct volume by 16
and 26% at the same doses. In addition, R18 had a significantly greater beneficial
effect in reducing cerebral oedema, when compared to NA-1 treatment.

Following the positive results obtained with R18 when administered 60 minutes after
stroke onset, its therapeutic window was further investigated. The effectiveness of R18
was examined when administered intravenously 2-hours after the onset of permanent
MCAO or transient MCAO of 180-minutes duration, or when administered intraarterially immediately after reperfusion following a 120-minute duration of MCAO.
R18 did not significantly reduced infarct volume in these studies. However, following

permanent MCAO R18 significantly reduced cerebral oedema.

NA-1 was also

ineffective in the transient MCAO studies.

The findings presented in this thesis have further confirmed the neuroprotective
properties of several poly-arginine and arginine-rich peptides. Although additional
studies are still required to evaluate R18 as a neuroprotective agent in stroke, the
peptide represents a promising lead agent with the findings of this thesis laying the
foundation for future pre-clinical and clinical studies.
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General introduction
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Introduction

Stroke is a devastating condition responsible for increasing morbidity and mortality
worldwide, with no clinically available pharmacological neuroprotective treatments.
For this reason, there is an urgent need for the development of a safe and widely
applicable neuroprotective agent for stroke patients. The development of an effective
neuroprotective agent for stroke would have the effect of reducing mortality,
improving patient quality of life and lessening the social and economic impact of this
devastating condition. Current interventions to minimise ischaemic brain injury are
largely limited to pharmacological (tissue plasminogen activator; tPA) and
endovascular (thrombectomy) reperfusion therapies, however the availability of a
neuroprotective agent that can be administered soon after stoke onset would provide
the best opportunity to preserve brain tissue when used alone and/or in combination
with reperfusion therapies.
Recent studies in A/Prof Meloni’s laboratory have demonstrated that poly-arginine
and arginine-rich peptides have potent neuroprotective properties in in vitro injury
models that mimic the effects of stroke (Meloni et al., 2014; Meloni et al., 2015ab).
In addition, in an in vivo study, poly-arginine R9 (R = arginine) has been shown to
reduce brain injury (infarct volume) in a permanent middle cerebral artery occlusion
(MCAO) model of stroke in the rat (Meloni et al., 2015a). However, in order to
determine the full neuroprotective potential of poly-arginine and arginine-rich
peptides as neuroprotective treatments for stroke, additional pre-clinical animal studies
are required. Consequently, the focus of this project was to undertake additional
exploratory studies to assess the neuroprotective efficacy of different poly-arginine
and arginine-rich peptides using permanent and transient MCAO models of stroke in
the rat.
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Stroke

Epidemiology

It is estimated that stroke is responsible for 9% of all deaths worldwide, making it the
second most common cause of death after ischaemic heart disease (Donnan et al.,
2008). Every year, about 15 million people worldwide suffer a stroke, and of these,
nearly six million die, and another five million are left permanently disabled. Stroke
is considered to be the second leading cause of disability, after dementia (Leys et al.,
2005; Pinkston et al., 2009), where in Australia, affects approximately 60,000
individuals per year (Australian Institute of Health and Welfare, 2009).

In developed countries, while the incidence of stroke is declining, the burden of stroke
is paradoxically increasing due to an ageing population and the ongoing epidemics of
diabetes, hypertension and obesity (Kim et al. 2015). However, in developing
countries, the incidence of stroke is increasing, mainly due to the increasing prevalence
of diabetes and obesity. In fact, approximately 80% of all people who have suffered a
stroke now live in low and mid-income countries (Truelsen et al., 2007). Hardly
surprisingly, approximately 2-4% of global healthcare costs are directed to stroke
(Donnan et al., 2008). In addition, as the mortality of stroke decreases, the demand for
treatments and social support is destined to rise over the coming years.

Stroke subtypes

Stroke occurs when there is a reduced blood supply to a localised brain region, and for
this reason is commonly referred to as focal cerebral ischaemia, especially in the
context of research. Stroke can be further subdivided into two subtypes, ischaemic
stroke and haemorrhagic stroke. Ischaemic stroke occurs due to a blockage in a brain
artery, typically due to thrombosis or embolism, and accounts for about 80% of all
cases of stroke. In comparison, haemorrhagic stroke occurs due to a rupture in a brain
artery and accounts for 15% of strokes. Haemorrhagic stroke mainly arises due to a
rupture of small-vessel aneurysms, with hypertension considered a major contributing
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factor. A small proportion of haemorrhagic strokes (1-5%) are the result of a ruptured
cerebral aneurysm and bleeding into the subarachnoid space (Donnan et al., 2008).

While not typically classified as a stroke, brain injury due to global cerebral ischaemia
occurs when blood flow to all or the majority of the brain is significantly reduced, as
occurs following cardiac arrest, severe hypotension and cerebral oedema. Due to its
high prevalence and high clinical burden, the experimental studies described in this
thesis mainly focus on ischaemic stroke.

Risk factors and aetiology of stroke

Risk factors associated with stroke include demographic factors (age, gender,
ethnicity), pathophysiological characteristics (blood pressure, blood cholesterol levels,
blood glucose levels, cardiovascular diseases), and behavioural factors (smoking,
alcohol consumption, diet, exercise). While some risk factors (Table 1.1) cannot be
modified by life style changes and pharmaceutical treatments, others (Table 1.2) are
modifiable.

Table 1.1 Non-modifiable risk factors for ischaemic stroke (adapted from Goldstein
et al., 2006).
Risk factor

Evidence

Increasing age

The incidence of stroke increases dramatically after age 65

Gender

Males show an incidence rate of 1.25 compared to women

Genetic factors

A positive family history of cerebrovascular disease is
considered a risk factor for stroke

Transient ischaemic

Patients presenting with a TIA have a risk of stroke

attack (TIA)

estimated at around 4% per year

Prior stroke

Patients with prior stroke are at higher risk of having a
subsequent stroke

Ethnicity

The probability of stroke in black individuals is nearly
twice that of white, while the incidence in hispanics falls
between these two groups, irrespective of lifestyle factors
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Table 1.2 Modifiable risk factors for ischaemic stroke (adapted from Goldstein et
al., 2006).
Risk factor

Evidence

Carotid

Complications of atheroma, such as thrombosis or

atherotromboembolia

embolism, are the most common causes of ischaemia
and cerebral infarction

Hypertension

High blood pressure is the most important modifiable
risk factor with proven correlation with cardiovascular
and cerebrovascular complications

Atrial fibrillation (AF)

AF causes the blood to pool and clot, increasing the risk
of stroke. Other types of heart disease also confer a
higher risk of stroke

Cigarette smoking

The relative risk for stroke is between 1.5 and 3 higher
in smokers, the extent of the increased risk depending
on the number of cigarettes smoked

Diabetes mellitus

Individuals with diabetes mellitus are at proven
increased risk of developing stroke

Hyperhomocysteinaemia

Studies have shown a strong association between stroke
and high plasma levels of homocysteine

Alcohol abuse

Alcohol abuse raises blood pressure and increases the
risk of stroke

Dyslipidaemia

Data demonstrate a direct correlation between increased
total and LDL cholesterol levels and the incidence of
extracranial carotid atherosclerosis

Obesity and inactivity

Obesity and a lack of physical activity are major risk
factors for cardiovascular diseases, including stroke

Haemostasis and other Studies have demonstrated the role of high levels of
blood disorders

fibrinogen and a high red blood cell counts as risk
factors for stroke
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Clinical aspects

The onset of symptoms following stroke is typically acute, and reflects the region of
the brain affected. Initially, symptoms are normally associated with some form of
paralysis to one side of the body. Nausea and vomiting are more commonly associated
with haemorrhagic stroke, unless the ischaemia affects the vertebrobasilar territory.
Mild to moderate headache occurs in about a quarter of ischaemic stroke patients,
while severe headaches are common in haemorrhagic stroke patients. Most patients
remain conscious during the early stages of stroke. The main clinical features of stroke
as defined by the cerebral arterial vessels affected are summarised in Table 1.3.

Table 1.3 Stroke classification per arterial territories involved (adapted from Fisher,
2009).
Affect artery

Symptoms

Anterior

Mutism onset, lower limb paresis, hemiparesis, motor aphasia,

cerebral

artery apraxia, sphincter incontinence, grasping, unilateral sensory

(ACA)

deficit, mood disorders, confusional state and hemineglect

Middle cerebral Hemianopia, lower limb paresis, motor aphasia, Broca’s aphasia,
artery (MCA)

Wernicke’s aphraxia, premotor syndrome of Luria, unilateral
sensory deficit, confusional state and hemineglect

Posterior

Hemianopia, visual impairment, complex dysfunctions (alexia,

cerebral

artery colour-blindness, agnosia and impaired visual memory),
anopsia, ataxia, Wernicke’s aphasia, apathy, hypoesthesia, pure

(PCA)

sensory ictus, confusional state and hemineglect
Cerebellar artery Nystagmus, vertigo, dysmetria, ataxia, lateropulsion, postural
territories

instability and dysarthria, paralysis of the V and VII cranial
nerves

Infarct

of

brainstem

the Paralysis of the eye movements, hemiparesis, emiatassia,
vertigo, paralysis of the III-VI and VII cranial nerves, paralysis
of

pharynx

and

larynx,

Bernard-Horner

hemianaestesia of the face and hemisoma anaesthesia

syndrome,
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Pathophysiology of stroke

The human brain comprises 2% of total body weight, but accounts for 20% of total
oxygen consumption. As a consequence, the brain is extremely sensitive to the effects
of reduced blood perfusion, and requires a constant supply of oxygen in order to
generate cellular adenosine triphosphate (ATP), which is used as a cellular fuel to
maintain neuronal membrane potential, and preserve calcium, sodium and potassium
cellular ionic gradients. To provide the necessary energy required for the maintenance
cellular homeostasis, the brain requires about 500 cc of oxygen and 75-100 mg of
glucose per minute (Madsen et al., 1993; Jain et al., 2010). When blood flow to a
region of the brain is reduced, the survival of the tissue depends on the intensity and
duration of ischaemia and the availability of collateral circulation (Frackowiak et al.,
1980).

Within a few minutes of the onset of cerebral ischaemia, the central core (brain tissue
most severely affected by ischaemia) of the ischaemic region is exposed to the most
dramatic reduction in blood flow and consequently undergoes acute brain injury.
Surrounding the central core is the penumbra, which consists of a zone of ischaemic
tissue less severely affected by the reduction in blood supply. Brain injury within the
penumbra occurs over several hours, and represents tissue that is potentially
salvageable after stroke onset with treatments such as endovascular and
neuroprotective therapies (Ginsberg et al., 1997; Figure 1.1).
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Figure 1.1 Brain showing the central ischaemic core surrounded by penumbra. Since
the onset of stroke, the progression of core and penumbra is a progressive process.

The pathophysiology of ischaemic brain injury is complex and involves numerous
processes, including energy failure, loss of cell ion homeostasis, excitotoxicity,
increased intracellular calcium levels, free radical-mediated toxicity, generation of
arachidonic acid products, acidosis, cytokine-mediated cytotoxicity, complement
activation, disruption of the blood-brain barrier (BBB), activation of glial cells,
leukocyte infiltration and inflammation (Won et al., 2002; Woodruff et al., 2011).
These are interrelated and co-ordinated events, which contribute to acute and delayed
brain injury.

The initial stages of the ischaemic cascade include oxygen-glucose deprivation and
ATP production failure. The lack of ATP synthesis causes the loss of ionic
homeostasis resulting in neuronal cell depolarisation, and the release and reduced
uptake of the neurotransmitter glutamate. High extracellular concentrations of
glutamate trigger excitotoxicity due to the over stimulation of N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
kainic acid (KA) receptor activation, causing excessive intracellular calcium influx
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(Novelli et al., 1988; Nicholls and Attwell, 1990; Goldberg and Choi, 1993;
McCulloch et al., 1993). When the lack of ATP production is sustained, acute cell
death and brain injury occurs, while if the ATP synthesis is only transiently or mildly
inhibited, delayed brain injury results.

In acute cell death, the raised levels of intracellular calcium ions lead to secondary
effects such as the activation of calcium sensitive catabolic enzymes (phospholipases,
endonucleases and calpains), a decrease in protein synthesis (Kleihues et al., 1975;
Burda et al., 1994; DeGracia et al., 1996), alteration in mitochondrial function
(Rehncrona et al., 1979; Almeida et al., 1995) and organelle and cell membrane
breakdown. Consequently cell begins to swell and lyse leading to death.

In delayed cell death, the raised levels of intracellular calcium cause milder effects
associated with lipid peroxidation (Bromont et al., 1989; Haba et al., 1991), oxidative
stress, free radical production (Kader et al., 1993; Chan, 2001), mitochondrial
dysfunction and altered cell signalling. In addition, multiple cell death promoting
signalling pathways are activated (e.g. MAPK, C-Jun, TNF, MMPs, NFKB, caspases,
ERK1/2) (Bouwmeester et al., 2004). Moreover, there are post-translational and
translocational protein changes (Rosemberg et al., 1996; Gillardon et al., 1997). The
combination of all of these events ultimately leads to cell death through mechanisms
associated with apoptosis, necroptosis, autophagy and necrosis (Lipton, 1999; Brott
and Bogousslavsky, 2000; Degterev et al., 2005).

In addition, cerebral ischaemia and cellular injury can stimulate an inflammatory
response and blood brain barrier disruption (Dirnagl et al., 1999), which can further
amplify the initial ischaemic injury pathways (Lee et al., 2000) (Figure 1.2).
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Figure 1.2 Summary of the major events associated with the ischaemic cascade and
neuronal cell death. Excitotoxicity and calcium overload cause the induction of several
ionic, biochemical and cellular cascades.

Ischaemic brain injury and neuroprotection – Important concepts

With respect to the ischaemic stroke injury cascade, several important concepts are
relevant when considering the development of an effective neuroprotective agent: 1)
most, if not all, of the pathological events activated during the cascade are potential
targets for intervention to limit brain injury; 2) the earlier the ischaemic cascade is
inhibited, the more likely it is that injury will be reduced; 3) targeting multiple aspects
of the ischaemic cascade will provide the best opportunity to limit damage; and 4) at
some point, the extent of ischaemic brain tissue becomes so severe that damage is
irreversible, even with the successful reperfusion of the ischaemic tissue.
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In addition to the considerations outlined above, the ideal neuroprotective agent should
be safe to administer, and preferably suitable for application in the field, as time is
critical in order to achieve maximum neuroprotection. Along with the ability to reduce
brain damage without reperfusion, the neuroprotective agent should also be capable of
prolonging the time window for salvageable penumbral tissue, and thereby allowing
additional time for the application of reperfusion therapies (i.e. tPA and/or
thrombectomy).

Current acute treatments for stroke

While stroke continues to have a devastating impact, several acute interventions have
been shown to improve patient outcomes (Donnan et al., 2008). These include rapid
admission to a specialised stroke unit, tPA thrombolysis, thrombectomy,
hemicranectomy and low dose aspirin therapy. The benefits and limitations of these
various acute interventions are discussed below.

Admission to a specialised stroke unit

Admission to a specialised multi-disciplinary stroke care unit (SCU) provides the best
opportunity for patients to receive optimal post-stroke care. Within a SCU, patients
receive blood pressure control, early mobilisation and effective venous
thromboembolism prevention, treatments proven to reduce mortality and sensorimotor
deficits by 20% (Langhorne et al., 1993). Admission to a SCU also reduces mortality
and improves outcomes by reducing the incidence of infection after stroke. For
example, the proper management of dysphagia and risk of aspiration with the use of
naso-gastric tubes, coupled with the utilisation of urinary catheters can reduce the risk
of lung and urinary tract infections, respectively.

tPA thrombolysis and thrombectomy

Currently, the most effective available treatment for ischaemic stroke is reperfusion
therapy using tPA, alone or in combination with thrombectomy (Berkhemer et al.,
2015; Campbell et al., 2015; Jovin et al, 2015). Intravenous tPA therapy aims to
dissolve clots formed in cerebral vessels in order to restore the blood flow to the
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affected brain region. It is estimated that successful or partial reperfusion occurs in
about 20-50% of patients, and that haemorrhagic transformation can occur in up to 7%
of patients. In addition, even though tPA can reduce neurological disability, the
treatment does not appear to improve the mortality rate associated with stroke (Hacke
et al., 2004).

Thrombectomy is an endovascular procedure performed under angiographic guidance
and utilises a clot-retrieving catheter in order to extract a blood clot from an occluded
vessel to allow restoration of blood flow. In 2015, five clinical trials (MR CREAN,
ESCAPE, EXTEND-IA, SWIFT PRIME and REVASCAT) confirmed the efficacy of
endovascular thrombectomy for improving stroke outcomes when compared with
patients receiving tPA therapy only (Goyal et al., 2016). Data from the thrombectomy
trials have demonstrated the benefit of the procedure for internal carotid and proximal
middle cerebral artery occlusion, while uncertainties remain regarding its effectiveness
for more distal occlusions (Campbell et al., 2016). Importantly, following
thrombectomy, the rate of intracranial haemorrhage is no higher than with tPA therapy
alone (Goyal et al., 2016).

Despite the effectiveness of reperfusion therapies, a number of limitations and
disadvantages have been documented. Both tPA and thrombectomy must be
performed as soon as possible post-stroke, because outcomes worsen the longer the
period of ischaemia, such that the therapeutic window for treatment is recognised to
be 3–4.5 hours post-stroke. It has been estimated that for every 30 minutes delay from
the time of stroke onset to reperfusion, the ability to achieve full sensorimotor recovery
decreases by 10% (Khatri et al., 2014). The narrow therapeutic window for reperfusion
therapy is further compounded by the time delays in getting patients to medical
facilities and the need for a brain scan (e.g. CT or MRI) to confirm a patient has
suffered a stroke, and to identify stroke subtype (e.g. ischaemic or haemorrhagic). In
addition, some hospitals, especially those in remote and rural areas and in developing
countries, may not have the necessary expertise to administer reperfusion therapies.
This is especially true for thrombectomy, which requires highly specialised staff and
equipment to perform the procedure, which may not always be available. For these
reasons, it is currently estimated that only between 5-15% of eligible stroke patients
receive tPA and/or thrombectomy (Donnan et al., 2008; Henninger and Fisher, 2016).
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However, efforts are being made to increase the number of patients eligible for
tPA/thrombectomy treatment by improving the early detection of cerebral salvageable
tissue by the use of magnetic resonance imaging (MRI) and head CT imaging. In
addition, it is possible that the development of an effective neuroprotective agent may
have the potential to extend the therapeutic time window of reperfusion therapies by
preserving or “freezing” penumbral tissue for prolonged periods.

Hemicraniectomy

Hemicraniectomy is a surgical procedure performed to reduce the effects of severe
intracranial hypertension unresponsive to other medical treatments following large
cerebral infarction and space-occupying brain oedema. This is the most devastating
form of ischaemic stroke and occurs in a very small percentage of patients, between 2
and 5 days after stroke (Frank, 1995) with a reported mortality rate of 80% (Hacke et
al., 1996). The surgical procedure involves removing a large section of skull to reduce
intracranial pressure and prevent brain herniation and subsequent brainstem
compression.

Acetylsalicylic acid (Aspirin)

Aspirin is an antiplatelet agent used clinically to prevent the development of blood
clots. It is mainly used as a stroke therapy in patients that have not received tPA
thrombolytic therapy, and is usually administered 1 to 2 days after the initial stroke
(Sandercock et al., 2014). When assessed in two clinical trials (IST, CAST), it appears
that the use of aspirin reduces the risk of a subsequent stroke and therefore its use has
mainly focused on stroke prevention. Some of the advantages of aspirin are its low
cost, ease of administration and proven safety.
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Other neuroprotective approaches under consideration

Hypothermia

Hypothermia has been demonstrated to decrease infarct size and improve outcomes in
numerous in vivo animal stroke studies (Meloni et al., 2013; Campbell et al., 2013),
and to improve outcomes in some clinical trials following cardiac arrest and neonatal
hypoxia-ischaemia (Wu and Grotta, 2013), but not consistently in ischaemic stroke.
Several clinical studies have established that therapeutic cooling is technically feasible
(Lyden et al., 2005) and safe (Hemmen et al., 2010) in awake stroke patients. However,
despite the proven neuroprotective effects in animal studies, some issues such as the
difficulty of achieving and maintaining a low body temperature, the management of
patient discomfort and shivering, and the ability to provide adequate sedation indicate
that hypothermia still presents some challenges in a clinical setting. In addition, it is
likely that patients may have to be admitted to an intensive care unit (ICU) during
hypothermia maintenance requiring measures to be taken to prevent potential harmful
side-effects such as an increased risk of infections, coagulopathies, decreased
gastrointestinal motility and electrolyte disturbances. While some hypothermia stroke
clinical trials still are underway, no study as yet has demonstrated proven efficacy in
stroke patients.

Cellular therapies

In recent decades, as the result of widespread interest in the potential of stem cells to
replace damaged tissue in stroke and other neuro-damaging disorders, the application
of stem cells as a new therapeutic agent for stroke has been explored. In several animal
stroke studies, the transplantation of stem cells (e.g. human mesenchymal stromal
cells) has shown to improve outcomes and/or reduce cerebral infarction (Yan et al.,
2016; Lees et al., 2012). However, despite showing promising results in terms of
outcome improvements, only a few clinical studies with a low number of participants
have so far tested the effects of stem cells therapy after stroke in humans (Chen et al.,
2016). Therefore, further and more comprehensive randomised trials are needed to
investigate the efficacy of stem cells therapy in a clinical setting. In addition, because
of ethical issues, concerns about tumour formation from transplanted cells and limited
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availability of immune-compatible engraftable cells (Bang et al., 2016), there remain
considerable hurdles that need to be overcome before stem cells can be used as a stroke
therapy in human trials.

Pharmacological therapies

Some recent compounds that have been considered as neuroprotective therapies for
stroke include the peptides TAT-NR2B9c (also known as NA-1) and JNKI-TAT (also
known as XG-102), as well as ginsenoside, uric acid, edaravone, fingolimod,
minocycline, natalizumab and glyburide. These compounds have been designed or
used to minimise various neurodamaging events associated with the ischaemic
cascade, including excitotoxicity, damaging cell death pathways, oxidative stress,
inflammation and vasogenic oedema. Since the focus of this PhD study is examining
a peptide treatment as a potential neuroprotective therapy for stroke, the discussion
below focuses on the TAT-NR2B9c and JNKI-1-TAT peptides.
TAT-NR2B9c neuroprotective peptide
The NR2B9c peptide is composed by 9 amino acids (KLSSIESDV). It is derived from
the intracellular terminal carboxyl region of the N-methyl-D-aspartate (NMDA)
receptor NR2B subunit protein. The NR2B9c peptide was developed to inhibit an
intracellular

domain

of

the

NR2B

protein

binding to

the

cytoplasmic

signalling/adaptor protein postsynaptic density-95 (PSD-95), which also binds
neuronal nitric oxide synthase (nNOS), and in doing so generates nitric oxide.
However, after excitotoxic NMDA receptor activation, the PSD-95-NR2B interaction
results in the over-stimulation of the nNOS and the excessive production of nitric oxide
(NO) and cell death. For in vitro cell culture and in vivo animal neuroprotection
studies, the NR2B9c peptide is fused to the arginine-rich cell penetrating peptide,
TAT, to allow the peptide to enter cells and cross the blood brain barrier.
Several studies both in vitro and in vivo have confirmed that the TAT-NR2B9c peptide
possesses neuroprotective properties. Table 2 in Chapter 2 provides a summary of the
animal studies that have assessed the neuroprotective actions of TAT-NR2B9c.
Importantly, one animal study assessing the effects of TAT-NR2B9c peptide in mild
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and severe transient middle cerebral artery occlusion (MCAO) in the macaque showed
that the peptide is effective in reducing the brain infarct size even when administered
3 hours after stroke onset in a 3.5 hour transient MCAO model (Cook et al., 2012).
In addition, in a clinical study involving the intravenous administration of TATNR2B9c at the end of endovascular procedures for the repair of intracranial
aneurysms, the peptide, based on MRI scans, was shown to reduce the number, but not
the volume, of ischaemic lesions compared to placebo (Hill et al., 2012). The TATNR2B9c peptide, which has been proven to be safe and well-tolerated, is currently
being assessed in a Phase III clinical trial (ESCAPE-NA1) for neuroprotective efficacy
in ischaemic stroke. Enrolment for the trial is based on selecting patients with a small
infarct core and good collateral circulation who undergo endovascular therapies.
JNKI-1-TAT neuroprotective peptide
JNKI-1 is a peptide composed by 20 amino acids (RPKRPTTLNLFPQVPRSQDT)
derived from the JNK binding domain of the c-Jun N-terminal kinase interacting
protein-1 (JIP-1). JIP-1 is a component of the scaffold protein responsible for the
interaction and activation of JNK. JNK is a c-Jun N-terminal protein kinase and one
of the three identified families of mitogen activated protein (MAP) kinase, involved in
the final steps of a stress-activated signalling pathway that leads to c-Jun activation
and other post-translational protein changes associated with cell death and/or
apoptosis. As the JNKI-1 peptide is a competitive inhibitor of the JNK interaction with
JIP-1, the inhibition of JNK activation is thought to be the mechanism by which the
peptide exerts its neuroprotection. Several studies both in vitro and in vivo have shown
that the JNKI-1-TAT peptide possesses neuroprotective properties. For a summary of
the results of animal studies that have assessed the neuroprotective actions of JNKI-1TAT, see Table 3 in Chapter 2.
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Poly-arginine and arginine-rich peptides and neuroprotection

As mentioned above, this project aims to extend previous findings that initially
identified

that

poly-arginine

and

arginine-rich

peptides

possess

intrinsic

neuroprotective properties. Neuroprotective poly-arginine and arginine-rich peptides
(hereafter referred to as arginine-rich peptides otherwise unless indicated) typically
range in size from 6 to 30 amino acids, and are positively charged due to the presence
of arginine residues. In addition, they have the capacity to cross the plasma membrane
and enter cells, and for this reason, are also known as cell penetrating peptides
(Munyendo et al., 2012). In addition, arginine-rich peptides also have the capacity to
cross the blood brain barrier and enter the brain.

The method of intracellular transduction by arginine-rich cell penetrating peptides can
vary between different peptides and cell types, but three main mechanisms are used:
1) direct penetration; 2) endocytosis; and 3) inverted micelle formation. Endosomal
mechanisms are thought to be the most common method used by arginine-rich peptides
for cell entry. Due to the membrane traversing properties of arginine-rich cell
penetrating peptides, they have been extensively used for the intracellular delivery of
agents in experimental in vitro and animal studies, as well as in clinical applications
(Hill et al., 2012; Meloni et al., 2015b).
Furthermore, due to the ability of arginine-rich peptides to cross the blood brain
barrier, they are commonly used for the delivery of potential therapeutics, including
neuroprotective agents (e.g. peptides and proteins) into the brain. Potential therapeutic
substances fused to arginine-rich peptides have been assessed in neuronal cell culture
and animal models that mimic neurodegenerative disorders, including stroke, epilepsy,
Parkinson’s and Alzheimer’s disease (Lai et al., 2005; Liu et al., 2006; Arthur et al.,
2007; Colombo et al., 2007, Nagel et al., 2008; Xu et al., 2008; Vaslin et al., 2009;
Meade et al., 2009; Craig et al., 2011). By far the most commonly used arginine-rich
cell penetrating peptide is the TAT peptide (YGRKKRRQRRR). For a summary of
studies that have used TAT and other arginine-rich peptides as carrier molecules to
deliver putative neuroprotective peptides into the brain for the treatment of
experimental stroke and related conditions, see Chapter 2.
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During neuroprotective studies using the TAT peptide as a carrier for the delivery of
putative neuroprotective peptides into cultured cells or into the brain, a modest
neuroprotective effect was observed by some for TAT peptide as a control (Xu et al.,
2008; Vaslin et al., 2009), including a study from A/Prof Meloni’s laboratory (Meade
et al., 2010). Subsequent studies by Meloni and colleagues demonstrated that other
arginine-rich cell penetrating peptides (e.g. R9, penetratin) also display
neuroprotective properties, however neuroprotective potency was several magnitudes
greater than that observed for the TAT peptide (Meloni et al., 2014). Furthermore, in
a later study by Meloni et al (2015a) examining the neuroprotective properties of polyarginine and arginine-rich peptides, it was demonstrated that neuroprotective efficacy
increased with increasing arginine content and that the peptide positive charge was
critical for neuroprotection. In addition, Meloni et al (2015a) demonstrated that the
poly-arginine peptide R9 reduces infarct volume when administered after permanent
middle cerebral artery occlusion stroke in the rat. Based of these findings, Meloni et
al (2015a) proposed that the neuroprotective action of TAT-fused “putative”
neuroprotective peptides (e.g. TAT-NR2B9c, JNKI-1-TAT) is largely, if not
exclusively, due to the TAT carrier peptide per se and/or the cargo peptide enhancing
the effects of TAT.

Poly-arginine-rich peptides and neuroprotection

While the neuroprotective mechanisms associated with arginine-rich peptides are still
being investigated, some confirmed and potential mechanisms have been identified.

Inhibition of calcium influx following glutamate excitotoxicity

Results by Meloni and colleagues using Fura-2 AM calcium imaging after glutamic
acid exposure in neuronal cultures showed that poly-arginine and arginine-rich
peptides (TAT, R9, R12, R15, BEN1079, PYC36-TAT, NR2B9c-TAT, JNKI-1-TAT,
protamine) reduce intracellular calcium levels (Meloni et al., 2015ab).

This

mechanism of action is in line with the other studies demonstrating that arginine-rich
peptides, including TAT-fused “putative” neuroprotective peptides (NR2BCT-TAT,
CBD3-TAT, R9-CBD3, R6) reduce glutamate excitotoxic calcium influx in cortical
neurons (Tu et al., 2010; Brittain et al., 2011; Moutal et al., 2015) and reduce NMDA
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evoked receptor currents in NR1-NR2 NMDA receptor-expressing oocytes (FerrerMontiel et al., 1998). In addition, several studies have demonstrated that TAT-fused
peptides and arginine-rich cell penetrating peptides can reduce the expression of cell
surface ion channels and receptors in neurons (Fan et al., 2009; Sinai et al., 2010;
Zhang et al., 2010; Brittain et al., 2011; Brustovetsky et al., 2014; García-Caballero et
al., 2014) and other cells (Fotin-Mleczek et al., 2005). More recently, Meloni and
colleagues have confirmed that the poly-arginine peptide, R12 and the TAT-NR2B9c
have the capacity to reduce cell surface levels of the NMDA receptor subunit protein,
NR2B in cultured cortical neurons (MacDougall et al., 2016).

Maintenance of mitochondrial function

Growing evidence indicates that arginine-rich peptides exert beneficial effects on
mitochondria (Rigobello et al., 1995). For example, studies have demonstrated that
arginine-rich peptides may limit complex I activity and reactive oxygen species
production (Zhao et al., 2004; Batandier et al., 2006), inhibit the opening of the
mitochondrial permeability transition pore (Guigas et al., 2004), protect cristae
architecture (Szeto et al., 2011) and prevent cytochrome c release (Birk et al., 2015).

It was demonstrated in human embryonic kidney cells (HEK293) that poly-arginine
peptides localise to mitochondria, and reduce rates of mitochondrial respiration,
membrane potential and levels of reactive oxygen species (Marshal et al., 2015).
Furthermore, Marshall et al (2015) have recently confirmed the neuroprotective
properties of poly-arginine peptides in an in vivo NMDA-induced retinal ganglion cell
excitotoxicity model and provided evidence that the peptides reduce neuronal
mitochondrial oxidative stress. Also of interest are recent studies surrounding the
arginine-rich Borna disease viral mitochondrial-targeting protein, X. The full-length
protein X, as well as an X-derived peptide fused to a cell penetrating peptide have been
shown to display neuronal, axonal, and mitochondrial protective properties
(Szelechowski et al., 2014; Ferre et al., 2016).
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Inhibition of proteolytic enzymes

Another mechanism whereby arginine-rich peptides may exert a neuroprotective effect
is through their ability to inhibit the calcium-dependent protein convertase enzyme,
furin, which processes precursor proteins into their biologically active products
(Cameron et al., 2000; Kacprzak et al., 2004; Fugere et al., 2007), an effect that may
be beneficial following brain ischaemia. Furin is a ubiquitously expressed convertase
involved in the enzymatic activation of matrix metalloproteinases (MMPs). In the
ischemic brain (Yokota et al., 2001; Yang et al., 2007), furin is up-regulated and can
activate MMP2, MMP3 and MMP14 (also known as MT1-MMP) (Tian et al., 2011).
Furthermore, MMP3 can activate MMP1, MMP7 and MMP9, and MMP14 can
activate MMP2 and MMP2 can activate MMP9 (Yang and Rosemberg, 2015; Turner
and Sharp, 2016). Significantly, following stroke MMP2, MMP3, MMP9 and MMP14
are associated with blood brain barrier disruption, cerebral oedema, haemorrhage,
leukocyte infiltration and progressive inflammatory reactions (Hosomi et al., 2005;
Yang et al., 2007; Yang and Rosemberg, 2015; Turner and Sharp, 2016; Hafez et al.,
2016), while MMP inhibition reduces blood brain barrier degradation, cerebral
oedema and tissue injury (Yang et al., 2007; Jin et al., 2010; Yang and Rosemberg,
2015; Hafez et al., 2016; Turner and Sharp, 2016).

Aims of the thesis

The aim of this project is to assess the neuroprotective efficacy of different polyarginine peptides and the arginine-rich peptide protamine in different rat stroke
models, the goal being to provide evidence that justifies and leads the way to additional
pre-clinical studies evaluating arginine-rich peptides as a potential treatment for
stroke.

The specific aims of the project are:

Aim 1: To assess the neuroprotective efficacy of poly-arginine peptides (R12, R15,
R18 and protamine) using a permanent MCAO rat stroke model.
Hypothesis – Poly-arginine and protamine peptides are neuroprotective following
permanent MCAO stroke.
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Aim 2: To determine the therapeutic time window and dose responsiveness of an
effective peptide (as identified in Aim 1) using a permanent MCAO stroke model.
Hypothesis – An effective peptide as identified in Aim 1 will have a therapeutic
window of between 1 to 6 hours after stroke onset.

Aim 3: To determine the therapeutic time window and dose responsiveness of an
effective peptide (as identified in Aim 1) in a transient MCAO stroke model.
Hypothesis – An effective peptide as identified in Aim 1 will also be effective in a
transient MCAO model.

Aim 4: To assess the neuroprotective efficacy of an effective peptide (as identified in
Aim 1) when administered post-reperfusion in a transient MCAO stroke model.
Hypothesis – Peptide administration post-reperfusion following transient MCAO
model will be effective.
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38
Materials and methods

In addition to information provided in publications (Chapters 4, 5, 6, 7 and 8), many
of the material and methods used in this project are also provided in this section of the
thesis.

Peptides used in this thesis

Poly-arginine and arginine-containing peptides

The peptides used in animal and in in vitro studies are summarised in Tables 3.1 and
3.2. All peptides except protamine sulphate (referred as protamine; Ptm), which was
purchased from Sanofi-Aventis (Perth, Australia), were purified using high
performance liquid chromatography to at least 98% purity. With the exception of
peptides used in the first study (R12, R15, R18) and protamine sulphate used for in
vivo and in vitro studies, the peptides were subjected to hydrolysis and amino acid
liquid chromatography analysis to obtain a precise measurement of peptide content
(Mimotopes, Melbourne, Australia). For animal studies, all peptides were prepared in
0.9% sodium chloride for injection (Pfizer, Perth, Australia), aliquoted into a 650 μl
volume within 3 ml syringes, and stored at -20°C until use. For additional details of
protamine derived peptides see Table 3.2 and Chapter 7 of the thesis.

Table 3.1 Summary of the peptides used in the study.
Peptide

Sequence*

Arginine Charge
residues at pH 7

R12

H-RRRRRRRRRRRR-OH

12

12

R15

H-RRRRRRRRRRRRRRR-OH

15

15

R18

H-RRRRRRRRRRRRRRRRRR-OH

18

18

R12W8a

H-WWRRRRWWRRRRWWRRRRWW

12

12

TAT-NR2B9c
(NA-1)

H-GRKKRRQRRR-KLSSIESDV-OH

6

7

* R = arginine, W = tryptophan, G = glycine, K = lysine, Q = glutamine, L = leucine,
S = serine, I = isoleucine, E = glutamic acid, D = aspartic acid, V = valine.
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Table 3.2 Protamine sulphate peptide used in the study.
Peptide
Ptm

Sequence*

Arginine Charge
residues at pH7

Mixture of protamine peptides Ptm 1 – 4

≈21

21

Ptm 1

PRRRRRSSSRPIRRRRRPRASRRRRRGGRRRR

21

21

Ptm 2

PRRRRSSRRPVRRRRRPRVSRRRRRGGRRRR

21

21

Ptm 3

PRRRRSSSRPVRRRRRPRVSRRRRRGGRRRR

20

20

Ptm 4

PRRRRASRRIRRRRRPRVSRRRRRGGRRRR

21

21

Ptm 5

PRRRRSSSRPVRRRRRPRVSRRRRRRGGRRRR

21

21

LMWP

VSRRRRRRGGRRRR

10

10

sulphate

* Ptm 1 – 4 were identified following high-performance liquid chromatography and
peptide sequence analysis of commercial preparations of protamine sulphate produced
from salmon milt (Hoffmann et al, 1990). Ptm sulphate is likely to consist of Ptm 1 –
4 as the sulphate salt. LMWP: low molecular weight protamine. P = proline, R =
arginine, S = serine, I = isoleucine, A = alanine, G = glycine, V = valine.

In vivo stroke models

Animal ethics approval

All animal surgical procedures and behavioural studies were approved by the
University of Western Australia Animal Ethics Committee and follow the guidelines
outlined in the Australian Code for the Care and Use of Animal for Scientific Purposes
and the National Health and Medical Research Council of Australia. In the design of
these studies, every effort was made to minimise the amount of animal suffering and
follow both the STAIR (Fisher, 2011) and ARRIVE (Kilkenny et al., 2010) guidelines
as appropriate.
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Middle cerebral artery occlusion (MCAO) stroke models

Most experimental stroke models rely on intravascular occlusion (Koizumi et al.,
1986; Longa et al., 1989; Belayev et al., 1996) or extravascular ligation (Tamura et al.,
1981a) to inhibit cerebral blood flow to a defined brain region. The most commonly
used stroke models use an intraluminal filament to occlude the middle cerebral artery.
An intraluminal filament procedure was utilised in this study and involved advancing
a silicone coated filament into the internal carotid artery until it reached the middle
cerebral artery bifurcation, and thereby blocking blood flow through the vessel. In this
procedure, MCAO can be permanent, if the filament is tied in place, or transient if the
filament is retracted, allowing for reperfusion.

Surgical procedure for the MCAO model

For this model, healthy Sprague Dawley (SD) rats weighing between 270 and 340
grams were used. Animals were fasted overnight, but allowed water ad libitum. Fasting
was performed to provide a more consistent blood glucose range between rats, which
improves model consistency. Anaesthesia was induced using a facemask with 4%
isoflurane in a gas mixture of 30% O2 and 70% of N2O, reducing the isoflurane to 2.0–
1.5% once the animal was anaesthetised, and during MCAO. If necessary animals were
warmed with a fan heater during surgical procedures to maintain body temperature at
37.0-38.0°C. Eye ointment was applied during the procedure to avoid eye dryness. The
tail artery was cannulated to allow blood pressure to be monitored and blood samples
to be removed (between 50-200 µl) for blood gases (pO2, pCO2), pH and glucose
measurements.

A midline incision was made in the scalp, and the top of the skull exposed. In the
earlier studies a dental drill was used to thin the bone of the skull over the right cerebral
hemisphere. In later studies, thinning of the skull bone was found to be unnecessary
for laser Doppler recording and was not performed. A laser Doppler probe holder was
attached to the skull using a fast-setting, non-toxic adhesive (loctite). Once attached, a
laser probe was inserted into the probe holder. The laser Doppler measures cerebral
blood flow by monitoring the velocity of moving red blood cells beneath the beam of
the laser.
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Through a longitudinal cervical skin incision, the right common carotid artery (CCA),
external carotid artery (ECA), and internal carotid artery (ICA) were exposed. The
ECA was ligated and a silicone coated nylon monofilament (Doccol, Redlands, CA,
USA) advanced (19-21 mm) into the ICA to occlude the middle cerebral artery (MCA)
(Belayev et al, 1996). In the permanent model, the thread was tied in place. However,
in the transient model, following 90 - 180 minutes of MCA occlusion, reperfusion was
achieved by retracting the filament. At the completion of the surgical procedure, the
laser Doppler probe, probe holder, and adhesive were removed, the wounds sutured
and the animal allowed to recover (Figure 3.1).

Figure 3.1 Intraluminal filament MCAO model in the rat. (A) An intraluminal
filament was advanced into the internal carotid artery until it blocked the MCA, which
was confirmed by a laser Doppler. Blood pressure was monitored and temperature
maintained at 37°C during surgical procedures. (B) & (C) Entire and coronal sections
of rat brain stained with TTC (triphenyl tetrazolium chloride). The red area represented
the viable tissue and the white area the brain infarct. CCA = common carotid artery,
ECA = external carotid artery, ICA = internal carotid artery, MCA = middle cerebral
artery, ACA = anterior cerebral artery.
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Post-surgical analgesia, animal body temperature monitoring and housing
At the conclusion of surgery pethidine was administered intramuscularly (1 mg in 0.2
ml saline) and bupivacaine was administered subcutaneously (0.1 mg in 0.2 ml saline
per site) to tail and head wounds. Animal body temperature was measured every 30–
60 minutes using a lubricated rectal probe and closely monitored for at least 2 hours
after surgery, and maintained between 37.0 and 37.8°C. To aid in the maintenance of
animal body temperature during surgical recovery, animals were housed in an holding
room maintained at 25-26°C, cages placed on heating pad and external heating via a
fan heater applied if necessary.

Functional testing

Focal cerebral ischaemia or stroke causes sensorimotor deficits in rats. Therefore, to
determine whether reduced brain infarction following treatment is also associated with
improved sensorimotor outcomes, three neurological tests were performed. Functional
assessment tests were performed before MCAO surgery (day before or on day of
surgery) and at experiment end-point (24 hours after stroke onset).

Neurological assessment test

Scoring of neurological injury/impairment was performed using the modified
Bederson’ scale (Bederson et al., 1986) and is summarised in Table 3.3. Because
sensory disturbance and loss of motor function are common outcomes of stroke, the
neurological assessment aims to assess the general animal well-being following stroke.
Scores range from 0 for no deficits, 1 for flexed forepaw, 2 for inability to resist lateral
push, 3 for circling, 4 for agitated circling and 5 for unresponsive to stimulation/stupor.

43
Table 3.3 Neurological assessment test.
Score

Neurological grading scale post-surgery

0

No deficits

1

Flexed forepaw

2

Inability to resist lateral push

3

Circling

4

Agitated circling

5

Stupor

Adhesive tape paw removal test

The bilateral asymmetry paw test assesses sensorimotor impairment. Each rat was
tested three times for each forepaw (before and after the surgery), by placing a 10 x 10
mm piece of adhesive tape (Cryo-Babies; Diversified Biotech, Boston), on the palmar
surface of the forepaw and the time taken for the first attempt to remove tape, the
number of attempts to remove tape and the total time taken to remove tape recorded.
A maximum of 120 seconds was allowed for animals to complete the task (normal rats
usually take between 5 to 30 seconds to remove the tape). Animals that failed to
remove the tape in the given time were scored 120 seconds.

Rota-Rod test

The Rota-Rod test was used to determine the balance and coordination of rats. This
test involves assessing the rat’s ability to remain walking on a rotating rod as it speed
of rotation is gradually increased from 4 to 40 revolutions per minute. The time in
seconds at which each animal falls (15-20 cm) onto a foam/sponge mattress was
recorded. Typically rats fall 15-100 seconds after placement on rod.

44
Ex vivo assessment of brain injury

Tissue sectioning and triphenyl tetrazolium chloride (TTC) staining

Twenty-four hours post-stroke animals were euthanised by lethal intraperitoneal
injection of pentobarbitone (325 mg of pentobarbitone sodium in 1 ml solution).
Infarct volume measurement was performed by brain slicing and TTC (triphenyl
tetrazolium chloride) staining. The brain was carefully removed from the skull and
placed in 0.9% saline and cooled for 7-10 minutes before being placed in a rodent
brain matrix. Razor blades were inserted into the matrix to generate 2 mm coronal
sections. The sections were incubated for 15–20 minutes in a 3% solution of TTC to
stain viable non-infarcted tissue, and then fixed in 4% formalin for at least 12 hours.

Measurement of ischaemic stroke damage in animal models

Digital images of coronal sections from brain slices were acquired with a colour
scanner and analysed using Image J Software (NIH) to calculate infarct volume.
Unstained tissue was defined as ischaemic infarcted areas. The area of infarcted tissue
and the area of both hemispheres were calculated for each brain slice. An oedema
index (cerebral hemispheric swelling/oedema) was calculated by dividing the total
volume of the stroke-affected hemisphere by the total volume of the contra-lateral
hemisphere. The actual infarct volume adjusted for oedema by dividing the infarct
volume for the oedema index. Once the infarct area for all coronal sections was defined
the total volume of the infarct was calculated (Table 3.6).
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Table 3.6 Description of steps used to for the measurement of infarct volume.

1) Open ImageJ.

ImageJ toolbar
2) Click on File  open the image of
interest. Check the spatial calibration
and set the correct pixel size.

Rat brain in 2 mm coronal sections
3) Draw a line over the scale bar and
select Analyze  Set Scale. In the set
scale window enter the selected line
into the ‘Known Distance’ box and set
the ‘Unit of Measurement’. When the
image is calibrated the number of
pixels and the dimensions in the
selected Unit of Length is displayed.

Set scale window in ImageJ
4) Once measurement parameters are
set, click on the Polygon Selections
button. With the image open, trace the
entire brain section by clicking and
outlining the perimeter of the brain.
When complete, click near the starting
point and the contour selection of the
brain will be shown. Select Analyze
 Measure. A Results box will
display the Area measurement and the
parameters selected.
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Entire perimeter of the brain
5) Follow this same tracing method
for the infarct area of the brain slice,
and again select Analyze  Measure.
The results block will show the area of
the infarct selection.

Perimeter of the infarct area
6) You may do this for all your tissue
sections. Determine the total volume
of the infarct and brain, and then
divide the infarct area by the brain
area to obtain the infarct volume as a
percentage of total brain volume.

Example of infarct volume analysis using ImageJ

Statistical Analysis

Data from physiological parameters, mean total infarct volume measurements (total
and coronal slices), and cerebral oedema for each treatment group were evaluated by
analysis of variance (ANOVA) followed by Fisher’s post hoc analysis. Data from
adhesive tape and rota-rod tests were evaluated by analysis of variance (ANOVA)
followed by Fisher’s post hoc analysis. Data from neurological assessment were
analysed using Kruskal-Wallis test. A value of p < 0.05 was considered as significant
for all data sets.
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Abstract
Background: We recently reported that poly-arginine peptides have neuroprotective properties both in vitro and
in vivo. In cultured cortical neurons exposed to glutamic acid excitotoxicity, we demonstrated that neuroprotective
potency increases with polymer length plateauing at R15 to R18 (R = arginine resides). In an in vivo study in rats,
we also demonstrated that R9D (R9 peptide synthesised with D-isoform amino acids) administered intravenously at
a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume.
Based on these positive in vitro and in vivo findings, we decided to examine the neuroprotective efficacy of the
L-isoform poly-arginine peptides, R12, R15 and R18 when administered at a dose of 1000 nmol/kg 30 min after permanent MCAO in the rat.
Results: At 24 h post-MCAO, there was reduced total infarct volume for R12 (12.8 % reduction) and R18 (20.5 %
reduction), but this reduction only reached statistical significance for R18. Brain slice analysis revealed significantly
reduced injury in coronal slices 4 and 5 for R18, and slice 5 for R12. The R15 peptide had no effect on infarct volume.
Peptide treatment did not reveal any statistical significant improvement in functional outcomes.
Conclusion: While these findings confirm the in vivo neuroprotective properties of poly-arginine peptides, additional dose studies are required particularly in less severe transient MCAO models so as to further assess the potential
of these agents as a stroke therapy.
Keywords: Poly-arginine peptides, Middle cerebral artery occlusion, Stroke, Neuroprotection
Background
Minimising brain injury following stroke is a critical
clinical goal both to improve patient quality of life and to
lessen the social and economic impacts of this devastating
disorder. Currently, the most effective stroke therapy is to
restore cerebral blood flow to a blocked artery using tPA
and thrombectomy [1–3]. However, the current therapeutic window for coupled tPA ± thrombectomy therapy
is so narrow (4.5 h) that the majority of stroke patients
are unable to receive the treatment. Moreover, for those
that do, up to 7 % develop intracranial haemorrhage as a
*Correspondence: bruno.meloni@wanri.uwa.edu.au
3
Western Australian Neuroscience Research Institute, A Block, 4th Floor,
QEII Medical Centre, Verdun St, Nedlands, WA 6009, Australia
Full list of author information is available at the end of the article

complication. In addition, tPA ± thrombectomy is only
available to patients having ready access to a hospital that
has the facilities required for performing the procedures.
Other treatments are only suitable for a small proportion
of patients (e.g. hemicraniectomy to reduce intracranial
pressure due to cerebral oedema) or provide only modest
benefit (e.g. aspirin to reduce risk of clot propagation) [4].
As a consequence, while recent improvements in stroke
therapy have been made, these have been limited and it
is clear that there is urgent need for new, more widely
applicable neuroprotective therapies that can be applied
to stroke patients early by ambulance paramedics, in hospital emergency departments, and in remote locations
away from tertiary hospitals. Additionally, any treatment that might improve the safety, therapeutic window

© 2016 Milani et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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and neuroprotective outcomes for tPA ± thrombectomy
would be of great clinical significance.
Against the backdrop of the limited nature of current
therapies, we have recently demonstrated that poly-arginine (and arginine-rich) peptides have potent neuroprotective properties in in vitro injury models that mimic
the effects of stroke [5–7]. We have also established that
poly-arginine peptides, as well as other arginine-rich
peptides, including TAT and penetratin belonging to a
class of peptide with cell penetrating properties also possess intrinsic neuroprotective properties [5–7]. Moreover, our in vitro data show that neuroprotective potency
is enhanced with increasing arginine content (e.g. polymer length) [6]. As evidence of their clinical applicability, we have demonstrated that the poly-arginine R9D
significantly reduces infarct volume in vivo following
permanent middle cerebral artery occlusion (MCAO) in
the rat [6]. A recent report [8] has also demonstrated that
poly-arginine 7 (R7) containing peptides are neuroprotective in an in vivo retinal ganglion NMDA excitotoxicity model.
The neuroprotective properties of poly-arginine peptides in vitro and in vivo suggest that they may have
potential as a neuroprotective therapy for stroke patients.
To further investigate the efficacy of poly-arginine peptides in vivo and given the positive results obtained with
the R9D peptide, in this study we assess the neuroprotective efficacy of the longer L-isoform poly-arginine
peptides R12, R15 and R18 when administered 30 min
after permanent MCAO. In addition, unlike in our earlier R9D trial, this study assesses functional outcomes
using three behavioural tests as well as infarct volume to
gain an understanding of the functional consequences of
neuroprotection.

Results
Physiological and infarct volume measurements

Physiological measurements before or during surgery
confirmed the absence of any significant differences
between animal treatment groups (Table 1). Data on
the mean total infarct volumes and representative TTC

stained coronal brain slices for each treatment group are
presented in Fig. 1. These results show that the R18 peptide significantly reduced infarct volume (20.5 % reduction; P = 0.014). The R12 peptide also reduced infarct
volume (12.8 % reduction), but not to a statistical significant extent (P = 0.105). By contrast, the R15 peptide
had no effect on infarct volume. Rostral to caudal topographic analysis of infarcts in brain slices revealed that
the R18 peptide significantly reduced brain injury in coronal slices 4 (P = 0.008) and 5 (P = 0.01) (Fig. 2). In addition, the R12 peptide significantly reduced brain injury in
coronal slice 5 (P = 0.027).
There were three post-treatment animal deaths that
occurred the day following surgery, one in the vehicle and
two in the R12-treated animals. While the animal deaths
could be directly related to stroke severity and/or treatment, the exact cause of the deaths could not be precisely
determined on autopsy.
Functional outcome assessment

Neurological scores using the modified Bederson’ scale for
each treatment group are presented in Fig. 3. While neurological scores did not differ statistically between groups,
the vehicle control group score was higher (1.9) than any of
the scores for the peptide treatment groups (<1.4), indicative of a possible positive treatment effect. Results for the
rota-rod assessment for each treatment group are presented in Fig. 4. Results were highly variable within groups
and no significant differences were detected.
For the adhesive tape removal test pre- and postMCAO measurements for time to detect tape, the number of attempts to remove tape and time taken to remove
tape for each treatment group are presented in Fig. 5.
As expected, the left paw was more adversely affected
than the right paw, however there were no statistically
significant differences between vehicle-treated versus
peptide-treated groups. However, for the R12 peptide all
parameters measured for the left paw, and two out of the
three measurements obtained for the right paw showed a
positive improvement, albeit not to a statistically significant extent.

Table 1 Physiological parameters for experimental animals used in study

PaO2 (mmHg)
PaCO2 (mmHg)
pH
Glucose (mmol/L)
Blood pressure (mmHg)
Body temperature (°C)

Saline (N = 12)

R12 (N = 9)

R15 (N = 8)

R18 (N = 8)

115.10 ± 33.51

124.30 ± 18.40

112.80 ± 16.96

120.60 ± 20.34

7.44 ± 0.09

7.33 ± 0.08

7.31 ± 0.09

7.42 ± 0.08

42.92 ± 5.82

7.74 ± 1.27

89.00 ± 8.44

37.48 ± 0.18

46.00 ± 4.21

7.42 ± 1.06

78.44 ± 6.98

37.58 ± 0.13

39.38 ± 5.20

7.03 ± 1.11

88.00 ± 9.97

37.46 ± 0.21

44.25 ± 7.74

7.13 ± 1.08

79.63 ± 12.65
37.51 ± 0.06

PaO2, PaCO2, pH, blood pressure and glucose measured before MCAO. Body temperature data represent average over 2 h post-surgery monitoring period. Data are
mean ± SD
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Fig. 3 Neurological grading scores 24 h after permanent MCAO
(0 = no deficit, 4 = major deficit) for saline (vehicle) and peptide
(R12, R15, R18; 1000 nmol/kg) treatment groups. Assessment was
performed immediately before euthanasia. Lines on graph indicate
range and median for neurological scores

Vehicle
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R15

R18

Vehicle

Time on rota-rod (seconds)

b

R12

R15

R18

Fig. 1 Infarct volume measurements and coronal brain slices 24 h
after permanent MCAO. Treatments were administered intravenously
(saline vehicle or peptide 1000 nmol/kg; in 600 µl volume over 6 min)
30 min after MCAO. a Values are mean ± SD. *P < 0.05 when compared to the vehicle control group. †Denotes animals that died the
following day after surgery, before the 24 h post-MCAO end-point,
but whose infarct volume was measured nonetheless. b Representative TTC coronal brain slices from vehicle and peptide treated animals
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Fig. 4 Rota-rod performance 24 h after permanent MCAO for saline
(vehicle) and peptide (R12, R15, R18; 1000 nmol/kg) treatment
groups. Results for this test were highly variable within groups and
no significant differences were detected. Average time healthy presurgery animals remained on rota-rod was 78 s (data not shown).
Values are mean ± SD

Weight loss measurement

At experiment end, all treatment groups recorded a loss
in weight, with the greatest weight loss occurring in the
R15 peptide treatment group (P = 0.004; Fig. 6).

Infarct volume (mm3)

110
Vehicle
R12
R15
R18
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Coronal brain slices (from rostral to caudal )

Fig. 2 Infarct volume analysis in coronal brain slices (1–6 from rostral
to caudal). The R18 peptide significantly reduced injury in brain slices
4 and 5, and the R12 peptide significantly reduced brain injury in slice
5. Values are mean ± SD; *P < 0.05 when compared to the vehicle
control group

Discussion
In a previous study, we demonstrated that the poly-arginine peptide R9D could reduce infarct volume by 20 %
when administered intravenously 30 min post-MCAO
[6], however no functional assessment was performed.
The present study extends this previous study to include
the poly-arginine peptides R12, R15 and R18 and explores
their capacity to reduce infarct volume and improve functional outcomes when administered intravenously 30 min
post-MCAO. Whereas R15 had no effect on infarct volume, R18 significantly reduced infarct volume (20.5 %
reduction) and there was a trend towards reduced infarct
volume with R12 (12.8 % reduction). Importantly, all peptide treatments displayed a trend towards improvement
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Fig. 5 Functional assessment measurements using adhesive tape removal test before and 24 h after MCAO for saline (vehicle) and peptide (R12,
R15, R18; 1000 nmol/kg) treatment groups. Post-MCAO assessment was performed immediately before euthanasia. No treatment significantly
improved adhesive tape detection or removal times for the left or right paw. Values are mean ± SD; N = 11 for vehicle, N = 7 for R12, N = 8 for R15
and N = 8 for R18. Maximum time allowed for adhesive tape removal was 120 s

in one or more of the neurological functional tests.
Whilst the level of infarct volume reduction was modest (12.8–20.5 %), this most likely reflects the severity of
the stroke model used in this particular study where up
to 90 % of the affected brain hemisphere is infarcted by
the stroke. It is also likely that the modest reductions in
infarct volume, stroke severity and 24-h endpoint coupled with the small animal numbers used explain why the
trend towards improvements in functional outcomes was

not statistically significant. Despite the modest effects of
the poly-arginine peptides following permanent MCAO,
it is still possible that these peptides have potential clinical application, especially in less severe forms of stroke,
stroke associated with cerebral reperfusion treatments
(tPA ± thrombectomy) and haemorrhagic stroke.
With respect to neuroprotective efficacy, further
research is required to determine the optimal dose of
the peptides to reduce infarct volume. It was particularly
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Fig. 6 Weight loss at 24 h after permanent MCAO for saline (vehicle)
and peptide (R12, R15, R18; 1000 nmol/kg) treatment groups. Values
are mean ± SD; *P < 0.05 when compared to the vehicle control
group

surprising that the R15 peptide did not have any affect
on infarct volume reduction, despite showing comparable neuroprotective efficacy to R18 when assessed in an
in vitro neuronal glutamate excitotoxicity model [6]. The
reason why no observable neuroprotection was obtained
for R15 is at present unknown, but it is possible that a
higher or lower dose may be more effective than the dose
used in the current study. Studies are currently underway
in our laboratory to more definitively address questions
surrounding effective dosage for a range of poly-arginine
peptides in the in vivo stroke model.
The present study did not investigate the mechanism
of action of peptides, but in previous studies we have
shown that poly-arginine peptides have the capacity to
reduce excitotoxic glutamic acid-induced calcium influx
in cultured cortical neurons [6, 7]. Based on this finding,
as well as the findings of other studies, we have hypothesised that these peptides have the capacity to inhibit calcium influx by causing the internalisation of cell surface
structures such as ion channels and thereby reduce the
toxic neuronal calcium entry that occurs after excitotoxicity and cerebral ischemia. We have speculated that due
to the cell penetrating properties of arginine-rich peptides, including putative “neuroprotective peptides” fused
to the arginine-rich carrier peptide TAT, ion channel
receptor internalisation occurs during neuronal endocytic uptake of the peptides [6, 7]. Evidence that supports our hypothesis includes studies demonstrating that
arginine-rich peptides: (1) interfere with the function
of NMDA [9–14] and vanilloid receptors [15], voltage
gated calcium channels [16–18] and the sodium calcium
exchanger [13]; (2) cause internalisation or reduced surface expression of neuronal ion channels [11, 13, 18]; and
(3) can induce the endocytic internalisation of epidermal
growth factor receptor and tumour necrosis factor receptors in HeLa cells [19].

In support of the poly-arginine neuroprotective findings in the present study, a recent report [8] has confirmed the neuroprotective properties of poly-arginine
7 (R7) containing peptides and other arginine-rich peptides (TAT and TATNR2B9c) in an in vivo retinal ganglion NMDA excitotoxicity model. Moreover, the study
also provides evidence for an additional neuroprotective
mechanism associated with maintenance of mitochondrial function and integrity.
Studies in our laboratory to confirm peptide-induced
internalisation of cell surface receptors and other neuroprotective mechanisms are in progress. While we have
demonstrated that arginine-rich peptides have the capacity to reduce excitotoxic calcium influx, it will be important to obtain a more comprehensive understanding of
peptide neuroprotective mechanism of action. Nevertheless our findings indicate poly-arginine peptides have
both in vitro and in vivo neuroprotective properties and
warrant further evaluation in different stroke models and
other acute brain injury disorders.

Conclusion
The findings of this study further validates the neuroprotective properties of poly-arginine peptides [5–9], highlights their status a new class of neuroprotective agent
and provides justification for their evaluation in different
stroke models and other acute brain injury disorders. The
findings also further question the mechanism of action of
the many reported “neuroprotective peptides” fused to
arginine-rich carrier peptides, which are thought to act
through interaction with specific intracellular proteins,
but which our data suggest may act through a common
mechanism of action relating to peptide arginine content
and positive charge.
Methods
Peptides

The R12 (H-RRRRRRRRRRRR-OH), R15 (H-RRRRRR
RRRRRRRRR-OH) and R18 H-RRRRRRRRRRRRRR
RRRR-OH) peptides used in the study were synthesised
by China Peptides (Shanghai, China). The peptides were
HPLC purified to >94 % purity. All peptides were prepared in 0.9 % sodium chloride for injection (Pfizer,
Perth, Australia) aliquoted into 650 µl volumes in 3 ml
syringes and stored at −20 °C until use.
Rat permanent middle cerebral artery occlusion procedure

This study was approved by the Animal Ethics Committee of the University of Western Australia and follows
guidelines outlined by the Australian Code for the Care
and use of Animals for Scientific Purposes. The experimental procedure for performing the permanent middle cerebral artery occlusion (MCAO) stroke model
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has been described previously [20, 21]. Briefly, male
Sprague–Dawley rats weighing 270–320 g were kept
under controlled housing conditions with a 12 h light–
dark cycle and with free access to food and water. Experimental animals were fasted overnight and subjected
to filament permanent MCAO. In order to monitor
blood pressure and withdraw blood samples, a cannula
was inserted in the tail artery. Between 50 and 200 µL
of blood was used for glucose (glucometer; MediSense
Products, Abbott Laboratories, Bedford, MA, USA) and
other measurements (PaO2, PaCO2, pH; ABL5, Radiometer, Copenhagen, Denmark). The MCAO procedure
was considered successful based on a >25 % decrease
from baseline in cerebral blood flow (CBF) after insertion of filament, as measured by laser Doppler flowmetry. During surgery temperature was closely monitored
using a rectal probe (Physitemp Instruments, Clifton,
USA) and maintained at 37.5 ± 0.5 °C, with fan heating
or cooling.
Thirty minutes post-MCAO, rats were intravenously
treated with the peptide (1000 nmol/kg in 600 µL over
6 min) or vehicle (0.9 % sodium chloride for injection;
600 µL over 6 min). Treatments were administered via
the right internal jugular vein and infusion pump. Treatments were randomised and all procedures were performed blinded to treatment.
Twenty-fours hours post-MCAO, infarct area assessment was performed by preparing 2 mm thick cerebral
coronal brain slices, and incubating in 3 % 2,3,5 triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St.
Louis, USA) at 37 °C for 20 min, followed by fixation
in 4 % formalin at room temperature overnight. Digital
images of coronal sections were acquired using a colour scanner and analysed by an operator blind to treatment status, using ImageJ software (3rd edition, NIH,
Bethesda, USA). The total infarct volume was determined by measuring the areas of infarcted tissue on
both sides of the 2 mm sections. These measured areas
were corrected for cerebral oedema by multiplying the
infarct volume for the oedema index (calculated by
dividing the total volume of the stroke-affected hemisphere by the total volume of the contralateral hemisphere) [22].
A total of 42 animals were used in the trial. Five animals were excluded from the study; two animals were
euthanased due to subarachnoid haemorrhage, one animal was excluded due to insufficient decrease in CBF, one
animal was excluded due to pyrexia, and one died during
surgical recovery for an unknown reason.
Post‑surgical monitoring

Following surgery animals were placed in a clean cage
with free access to food and water. The body temperature

of animals was measured every 30–60 min using a rectal probe for at least 2 h post-surgery, and maintained
between 37.0 and 37.8 °C. To avoid hypothermia, rat cages
were placed on a heating mat during the post-surgical
monitoring and housed in a holding room maintained at
26–28 °C. If necessary, additional heating or cooling was
performed by applying fan heating or cold water spray.
Behavioural testing

To determine if peptide treatment was associated with
improved sensorimotor outcomes, three neurological
tests were performed 24 h post-stroke.
Neurological assessment test

The scoring system was performed using the modified
Bederson’ scale. Scores range from 0 for no deficits, 1 for
flexed forepaw, 2 for inability to resist lateral push, 3 for
circling, 4 for agitated circling and 5 for unresponsive to
stimulation/stupor [23].
Adhesive tape removal test

This is a bilateral asymmetry paw-test, which assesses
sensorimotor impairment [24]. Adhesive tape (Diversified Biotech, Dedham, USA) 10 mm × 10 mm in size
was placed on the palmar surface of the forepaw and the
time taken for the first attempt to remove tape, the number of attempts to remove tape and the total time taken
to remove tape recorded. Each forelimb was assessed
sequentially starting with the unaffected side (right
side) with animals having a maximum of 120 s to complete the task (normal rats usually take between 5 and 30
s to remove the tape). Animals were tested a total of six
times, three times on the day before surgery and three
times 24 h post-MCAO. Mean values were calculated for
each forepaw for the pre- and post-surgery trials.
Rota‑rod test

This test assesses balance and coordination by assessing a
rat’s ability to remain walking on a rotating rod when its
speed of rotation gradually increases from 4 to 40 revolutions per minute. The time at which the animal falls is
recorded. Typically rats fall 27–137 s after placement on
the rod.
Statistical analysis

Mean infarct volume measurements (total and coronal
slices) for each treatment group was compared to the
vehicle control group by analysis of variance (ANOVA)
followed by the Fisher’s post hoc analysis. Data from neurological assessment were analysed using Kruskal–Wallis
test [25]. Data from adhesive tape and rota-rod tests were
analysed using ANOVA followed by post hoc analysis
using Scheffe’s multiple comparison procedure. A value
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of P < 0.05 was considered significant for all data sets.
Data in figures are presented as mean ± standard deviation (SD).
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We examined the dose responsiveness of polyarginine R18 (100, 300, and 1000 nmol/kg) when administered 60 minutes after
permanent middle cerebral artery occlusion (MCAO). The TAT-NR2B9c peptide, which is known to be neuroprotective in rodent
and nonhuman primate stroke models, served as a positive control. At 24 hours after MCAO, there was reduced total infarct volume
in R18 treated animals at all doses, but this reduction only reached statistical significance at doses of 100 and 1000 nmol/kg. The
TAT-NR2B9c peptide reduced infarct volume at doses of 300 and 1000 nmol/kg, but not to a statistically significant extent, while
the 100 nmol/kg dose was ineffective. The reduction in infarct volume with R18 and TAT-NR2B9c peptide treatments was mirrored
by improvements in one or more functional outcomes (namely, neurological score, adhesive tape removal, and rota-rod), but not
to a statistically significant extent. These findings further confirm the neuroprotective properties of polyarginine peptides and for
R18 extend its therapeutic time window and dose range, as well as demonstrating its greater efficacy compared to TAT-NR2B9c in
a severe stroke model. The superior neuroprotective efficacy of R18 over TAT-NR2B9c highlights the potential of this polyarginine
peptide as a lead candidate for studies in human stroke.

1. Introduction
While the incidence of stroke is falling in developed countries, it remains a leading cause of death and disability
worldwide, with an increasing global disease burden due to
an aging population, as well as the ongoing epidemics of
diabetes, hypertension, and obesity [1]. In terms of acute
therapies, for ischaemic stroke, reperfusion therapy using
tPA (tissue plasminogen activator) alone or more recently in
combination with thrombectomy is by far the most effective
treatment intervention currently available [2–6]. However,
despite the success of tPA/thrombectomy therapy, the number of stroke patients that receive this treatment is relatively
small. This is due to a combination of factors including
the narrow therapeutic time window for tPA/thrombectomy
(3–4.5 h after stroke), delays in patients obtaining medical

care, the requirement for a brain scan to exclude haemorragic stroke, and the need for highly trained personnel and
specialised equipment to perform the intervention. Given
these limitations, the search continues for a neuroprotective
agent that can be safely administered early after stroke
onset to limit the extent of brain injury after stroke and
that can be used when reperfusion interventions cannot be
implemented. Additionally, any neuroprotective treatment
that improves the efficacy, safety, and therapeutic window for
tPA/thrombectomy would be of great clinical significance.
In terms of neuroprotective agents, our laboratory has
recently demonstrated that polyarginine and arginine-rich
peptides have potent neuroprotective properties in in vitro
injury models that mimic the effects of stroke [7–9]. Moreover, we have extended these in vitro findings by demonstrating that the polyarginine peptides R9, R12, and R18

62
Stroke Research and Treatment
significantly reduce infarct volume in a permanent middle
cerebral artery occlusion (MCAO) stroke model [8, 10].
Based on these in vitro and in vivo findings, we have
recently proposed [8, 9] that arginine-rich peptides including
“neuroprotective peptides” fused to arginine-rich cell penetrating peptides (e.g., TAT-NR2B9c [11] and TAT-JNKI-1 [12])
represent a new class of neuroprotective agents for which
arginine residues are critical for neuroprotection.
In the present study, we further evaluate the efficacy of
the R18 polyarginine peptide by examining its dose responsiveness and by extending the treatment administration time
from 30 minutes to 60 minutes after permanent MCAO.
In parallel, the study compares the efficacy of R18 with
that of TAT fused NR2B9c peptide (TAT-NR2B9c), which
has previously been demonstrated to be neuroprotective
in various rodent and nonhuman primate stroke models
and to reduce ischaemic brain lesions in humans following
endovascular repair of ruptured aneurysms [11, 13–15].

2. Materials and Methods
2.1. Peptides Used in the Study. The R18 (HRRRRRRRRRRRRRRRRRR-OH) and TAT-NR2B9c (HYRKKRRQRRR-KLSSIESDV-OH, also known as NA-1)
peptides used in the study were synthesised by Mimotopes
(Melbourne, Australia). The peptides were HPLC-purified to
98% purity and were subject to peptide hydrolysis and amino
acid liquid chromatography analysis to obtain a precise
measurement of peptide content (Mimotopes). The peptides
were prepared in 0.9% sodium chloride for injection (Pfizer,
Perth, Australia), aliquoted into a 650 𝜇L volume in a 3 mL
syringe and stored at −20∘ C until use.
2.2. Surgical Procedure for Permanent Middle Cerebral Artery
Occlusion. The surgical procedures for permanent middle
cerebral artery occlusion (MCAO) as well as behavioural
and histologic assessment were performed in accordance
with the Animal Ethics Committee of the University of
Western Australia and following the guidelines outlined by
the Australian Code for the Care and Use of Animals for
Scientific Purposes.
The filament permanent MCAO stroke model as performed in our laboratory has been described previously [10,
16]. Briefly, male Sprague-Dawley rats weighing 275–340 g
that had been fasted overnight underwent facemask anesthesia with 4% of isoflurane (mix 30% oxygen/70% nitrous
oxide) and maintenance with 2% isoflurane. The tail artery
was cannulated to allow blood pressure monitoring and for
measurement of arterial blood gases (pO2 , pCO2 ), pH, and
glucose. The MCAO procedure was considered successful if
there was a >25% decrease from baseline in cerebral blood
flow after insertion of the filament, as measured by laser
Doppler flowmetry. During surgery, body temperature was
closely monitored using a rectal probe (Physitemp Instruments, Clifton, USA) and maintained at 37–37.8∘ C, with fan
heating or cooling, as required.
At sixty minutes after MCAO rats were treated intravenously through the right internal jugular vein using an
infusion pump with the vehicle (0.9% sodium chloride,

600 𝜇L over 6 min) or with three different doses of the peptide
(R18 or TAT-NR2B9c: 100, 300, or 1000 nmol/kg, 600 𝜇L over
6 min). Treatments were randomised and all procedures were
performed while being blinded to treatments.
Fifty male Sprague-Dawley rats underwent surgery for
permanent MCAO. Eight animals were excluded from the
study: five animals were excluded due to an insufficient
decrease in cerebral blood flow following MCAO, one was
excluded due to death during anesthetic induction, and two
animals were excluded because no obvious infarct lesion
was detected 24 hours after MCAO (one saline and one R18
100 nmol/kg treated animal). A further six animals died several hours before the 24-hour post-MCAO study end-point
but were still included in the final infarct volume analysis.
These animals comprised two R18 treated (one 100 nmol/kg
and one 1000 nmol/kg) and four TAT-NR2B9c treated (two
100 nmol/kg, one 300 nmol/kg, and one 1000 nmol/kg) animals. While the exact cause of the deaths could not be
determined, it is possible that it reflects the severity of the
stroke in this model, which is known to result in up to 90%
of the affected hemisphere being infarcted by the stroke. For
infarct volume analysis each treatment group consisted of
six animals. Due to animal deaths before the 24-hour study
end-point, four to six animals per group were available for
behavioural testing.
2.3. Postsurgical Monitoring. The body temperature of animals was measured every 30–60 minutes using a rectal probe
for at least 2 hours after surgery and maintained between 37.0
and 37.8∘ C. To avoid hypothermia, rat cages were placed on a
heating mat during the postsurgical monitoring and housed
in a holding room maintained at 26–28∘ C. If necessary,
additional heating or cooling was performed by applying fan
heating or a cold water spray.
2.4. Infarct Volume Assessment. Infarct volume was assessed
24 hours after MCAO as previously described [17]. Briefly
2 mm cerebral coronal brain slices were stained in 3% 2,3,5triphenyltetrazolium chloride (Sigma-Aldrich, St. Louis,
USA). Digital images of coronal brain slices were acquired
and analysed using ImageJ software (3rd edition, NIH,
Bethesda, USA) by an operator blind to treatment status. The
total infarct volume was determined by measuring the areas
of infarcted tissue on both sides of the 2 mm sections and
corrected for cerebral oedema [17].
2.5. Behavioural Testing. In order to assess if any treatment
improved sensorimotor outcomes, three behavioural tests
were performed 24 hours after MCAO. A neurological
assessment was performed using a five-point scale (0−5)
developed by Bederson et al. [18]. Scores range between 0
for no deficits, 1 for flexed forepaw, 2 for inability to resist
lateral push, 3 for circling, 4 for agitated circling, and 5 for
unresponsiveness to stimulation/stupor. The adhesive tape
removal test is a bilateral asymmetry paw test to assess
sensorimotor impairment [19]. Adhesive tape (Diversified
Biotech, Dedham, USA) 10 mm × 10 mm in size was placed
on the palmar surface of the forepaw and the time taken for
the first attempt to remove tape (time to detect tape), the
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Table 1: Physiological parameters (mean ± SD).

PaO2 , before MCAO
PaCO2 , before MCAO
pH, before MCAO
Glucose (mmol/L), before
MCAO
BP (mmHg), average during
surgery
Temperature (∘ C), average 2 h
after surgery

Vehicle (saline)
117.19 ± 22.44
38.33 ± 2.94
7.36 ± 0.05

100

Experimental groups
R18 (nmol/kg)
300
1000

100

TAT-NR2B9c (nmol/kg)
300
1000

114.66 ± 11.34 115.16 ± 13.79 124.16 ± 14.35 109.33 ± 9.04 117.83 ± 16.55 112.83 ± 12.93
39 ± 3.57
39.5 ± 3.50 42.68 ± 6.17 43.66 ± 8.93 39.5 ± 5.78 39.83 ± 3.74
7.42 ± 0.09
7.37 ± 0.04
7.44 ± 0.06
7.38 ± 0.04
7.45 ± 0.04
7.39 ± 0.06

8.0 ± 1.37

8.15 ± 0.68

7.81 ± 0.96

8.11 ± 1.00

7.21 ± 1.31

7.71 ± 0.81

7.50 ± 1.73

87.33 ± 4.17

88.33 ± 7.06

84 ± 5.13

91.6 ± 5.44

91 ± 3.09

83.66 ± 6.34

88 ± 3.68

37.51 ± 0.16

37.37 ± 0.25

37.46 ± 0.29

37.46 ± 0.21

37.43 ± 0.25

37.53 ± 0.17

37.52 ± 0.21

time taken to remove the tape, and the number of attempts
to remove tape were recorded. Each forelimb was assessed
sequentially starting with the unaffected side (right side) with
animals having a maximum of 120 seconds to complete the
task (normal rats usually take between 5 and 30 sec to remove
the tape). Each rat was assessed three times on the day prior to
the surgery and once 24 hours after MCAO. The rota-rod test
assesses balance and coordination by assessing a rat’s ability
to keep walking on a rotating rod, with the speed of rotation
being progressively increased from 4 to 40 revolutions per
minute. The time the animal falls was recorded.
2.6. Statistical Analysis. Total infarct volume and physiological parameters were evaluated by analysis of variance
(ANOVA) followed by Fisher’s post hoc analysis. The neurological assessment measurements were analysed using
Kruskal-Wallis test. Data from adhesive tape removal and
rota-rod tests were analysed using ANOVA followed by
Scheffé’s multiple comparison post hoc analysis. 𝑃 < 0.05
was considered as significant. Data are presented as mean ±
standard deviation (SD).

3. Results
3.1. Physiological Data, Infarct Volume Measurements, and
Animal Deaths. Physiological parameters measured during
surgery and before MCAO were within the normal range and
did not differ significantly between animal treatment groups
(Table 1).
Data on the mean total infarct volumes for each treatment
group are presented in Figure 1. These results show that the
R18 peptide significantly reduced infarct volume at doses of
100 nmol/kg and 1000 nmol/kg by 19.7% (𝑃 = 0.043) and 24%
(𝑃 = 0.013), respectively, while, at the 300 nmol/kg, infarct
volume was reduced by 12% (𝑃 = 0.19), albeit not to a statistically significant extent. By contrast, while the TAT-NR2B9c
peptide at doses of 300 nmol/kg and 1000 nmol/kg reduced
infarct volume by 6.8% (𝑃 = 0.56) and 7% (𝑃 = 0.55),
respectively, these effects were not statistically significant.
At 100 nmol/kg, TAT-NR2B9c was ineffective in reducing
infarct volume. In comparative terms, at 100 nmol/kg R18 was
significantly more effective in reducing infarct volume than
TAT-NR2B9c (19.7% versus 1.1%, 𝑃 = 0.045).

Infarct volume (mm3 )

Parameter

600

#∗ P = 0.19
†

400

∗

†

†

†

†

†

200
0

Vehicle

100

300
R18

1000

100

300
1000
TAT-NR2B9c

Figure 1: Infarct volume measurements 24 hours after permanent
MCAO. Treatments were administered intravenously (saline vehicle
or R18 and TAT-NR2B9c peptide at 100, 300, or 1000 nmol/kg;
600 𝜇L volume over 6 min) 60 minutes after MCAO. Values are
mean ± SD. ∗ 𝑃 < 0.05 when compared to the vehicle control group
and # 𝑃 < 0.05 when compared to the TAT-NR2B9c 100 nmol/kg
group. † denotes animals that died several hours before the 24-hour
post-MCAO study end-point but were still included in the final
infarct volume analysis.

3.2. Functional Outcome Assessment. Although not statistically significant, there was a trend towards improvement in
the performance in some of the behavioural parameters measured for R18 and TAT-NR2B9c treatment groups (Figures
2–4). Neurological scores for 100, 300, and 1000 nmol/kg
R18 treatment animals showed improved outcomes compared
with the vehicle-treated controls (Figure 2). By contrast,
for TAT-NR2B9c, only the 1000 nmol/kg treatment group
was associated with an improvement in neurological score
compared to vehicle. Measurements for the adhesive tape
test after MCAO were variable; however, treatment with the
300 nmol/kg R18 or 1000 nmol/kg TAT-NR2B9c appeared
to improve the time required to detect tape from the right
paw of the nonaffected forelimb, while the 100 nmol/kg TATNR2B9c treatment appeared to improve the time required
to detect tape from the left paw (Figure 3(a)). Similarly, the
number of attempts required to remove the tape from the
right and left paw was increased in animals treated with
1000 nmol/kg and 100 nmol/kg TAT-NR2B9c, respectively
(Figure 3(b)). Additionally, treatment with 1000 nmol/kg R18
was associated with the shortest time to remove tape from
the right paw (Figure 3(c)). For the rota-rod test, the group
receiving 100 nmol/kg R18 was the only treatment group
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Figure 2: Neurological grading scores 24 hours after permanent
MCAO (0 = no deficit, 5 = major deficit) for saline (vehicle)
and peptide (R18 and TAT-NR2B9c at 100, 300, or 1000 nmol/kg)
treatment groups. Lines on graph indicate range and median for
neurological scores.

that displayed an increased time to remain on the rotating
cylinder when compared to vehicle (118 sec versus 77 sec,
Figure 4).
3.3. Weight Loss Measurement. All groups recorded a loss in
body weight 24 hours after MCAO ranging from 28.5 grams
for the TAT-NR2B9c 100 nmol/kg treatment group to ≈34.5 g
for the 300 nmol/kg R18 and TAT-NR2B9c treatment groups
(Figure 5).

4. Discussion
The results of the present study add to our previous findings,
which showed that 1000 nmol/kg R18 when administered 30
minutes after permanent MCAO significantly reduces infarct
volume in the rat [10]. Importantly, we now show that R18 is
effective over an even wider therapeutic window (60 min) and
broader dose range (100–1000 nmol/kg) and that, on balance,
R18 is more effective than the extensively characterised
neuroprotective peptide, TAT-NR2B9c. Treatment with R18,
as well as to a lesser extent TAT-NR2B9c, resulted in some
functional recovery as assessed by behavioural tests, but not
to statistically significant levels, which most likely reflects the
severity of the stroke model used coupled with the relatively
small numbers of animals in the study. Notwithstanding
these limitations, our findings highlight the potential clinical
applicability of R18 as a therapeutic intervention in stroke,
especially in light of evidence that it is superior as a neuroprotective agent to TAT-NR2B9c, which is planned to enter
a phase 3 clinical trial in stroke patients [20]. The superior
neuroprotective efficacy of R18 compared to TAT-NR2B9c
is consistent with our in vitro findings in a glutamic acid
induced neuronal excitotoxicity model of cell death [8].
The TAT-NR2B9c peptide has been shown to be neuroprotective in rodent [11, 21–25] and nonhuman primate
stroke models [13, 14] and has been found to be safe and
cause a nonsignificant reduction in ischaemic brain lesions
in patients undergoing aneurysm surgery [15]. The NR2B9c
peptide (KLSSIESDV) is derived from the intracellular terminal carboxyl region of the N-methyl-D-aspartate (NMDA)
receptor NR2B subunit protein [11] and is fused to the
arginine-rich TAT peptide (YRKKRRQRRR) to allow entry
into the brain and neuronal cells. The NR2B9c peptide was
designed to act as a competitive inhibitor of the PSD-95

adaptor protein (postsynaptic density-95) binding to the
NR2B subunit protein and, in doing so, to block downstream
cell signaling associated with overstimulation of the NMDA
receptor, leading to nitric oxide synthase activation and
subsequent production of nitric oxide; however, we [9]
and others [25, 26] have proposed other mechanisms for
neuroprotection.
As an alternative mechanism, we have proposed that
the neuroprotective properties of TAT-NR2B9c are largely
mediated by the TAT peptide itself [9], which we [7, 27] and
others [28, 29] have previously reported to display modest
neuroprotective properties. Furthermore, due to the TAT
peptide’s arginine content and positive charge, it is likely
to possess a similar mode of action as polyarginine and
arginine-rich peptides [8, 9]. For arginine-rich peptides, we
have previously hypothesised that at least in part neuroprotection is related to the ability of these peptides to transverse
cell membranes and, in doing so, decrease the levels of cell
surface ion channels and receptors, thereby reducing the toxic
influx of calcium that occurs in neurons following cerebral
ischaemia [8, 9]. This mechanism of action is in line with
the confirmed ability of arginine-rich peptides to reduce
glutamate excitotoxic calcium influx in cortical neurons [8,
9, 30–32] and evoke receptor currents in NR1-NR2 NMDA
receptor-expressing oocytes [33], as well as the observation
that peptide neuroprotective efficacy correlates with peptide
endocytic or cell membrane transversing properties [34].
In addition, several studies have demonstrated that TAT
fused peptides and arginine-rich cell penetrating peptides
can reduce the expression of cell surface ion channels and
receptors in neurons [26, 31, 35–38] and other cells [39].
There is evidence to indicate that arginine residues
are critical elements for peptide and protein mitochondrial
uptake [40–43] and that arginine-rich peptides exert beneficial effects on mitochondria. For example, in isolated rat
liver mitochondria, cationic tetra- and polycationic peptides
and especially those containing arginine were highly effective
in blocking calcium induced mitochondrial swelling and
in maintaining membrane potential [44]. Similarly, cationic
compounds including tetrapeptides containing an arginine
residue (e.g., SS-20, SS-31) or biguanidines (e.g., metformin)
have been shown to target mitochondria and exert positive
effects on the organelle by limiting complex I activity and
reactive oxygen species production [41, 45], inhibiting the
opening of the mitochondrial permeability transition pore
[46], protecting cristae architecture [47], accelerating ATP
recovery [47], and preventing cytochrome c release [48].
While the exact mechanisms for these beneficial effects on
mitochondria are not fully known, the ability of cationic
guanidino groups to interact with anionic phosphate groups
of mitochondrial membrane phospholipids especially the
inner membrane phospholipid cardiolipin (−2 net charge)
may be a contributing factor.
Recently, Marshall et al. [49] confirmed the neuroprotective properties of polyarginine peptides in an in vivo
NMDA-induced retinal ganglion cell excitotoxicity model
and provided evidence that the peptides reduce neuronal
mitochondrial oxidative stress. Furthermore, it was demonstrated in HEK293 cells that polyarginine peptides localise to
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Figure 3: Functional assessment measurements using adhesive tape removal test before and 24 hours after MCAO for saline (vehicle) and
peptide (R18 and TAT-NR2B9c at 100, 300, or 1000 nmol/kg) treatment groups. (a) Time to detect tape. (b) Number of attempts to remove
tape. (c) Time to remove tape. Values are mean ± SD. Maximum time allowed for adhesive tape removal was 120 seconds.
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Figure 4: Rota-rod performance 24 hours after permanent MCAO
for saline (vehicle) and peptide (R18 and TAT-NR2B9c at 100, 300,
or 1000 nmol/kg) treatment groups. Values are mean ± SD.

Weight loss (gm)

40
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Taken together, the results from the current study support
other findings from our laboratory [8–10] and suggest that
polyarginine and arginine-rich peptides may represent a
new class of neuroprotective agents with enormous clinical
potential for the treatment of acute and chronic neurological
injuries. Importantly, it is possible that the reported beneficial
effects of arginine-rich cell penetrating peptides fused to a
“neuroprotective peptide” in animal studies of acute brain
injury are largely attributable to the effects of the arginine
residues contained within the peptide [9]. This adds to the
growing weight of evidence suggesting that arginine-rich
peptides (including R18) may be beneficial in a range of
acute clinical neurological disorders. There is also evidence
that arginine-rich peptides may improve functional recovery
from central nervous system injury as evidenced by experimental studies on the effects of TAT-NR2B9c in stroke [60]
and TAT-ISP in spinal cord injury [61]. Consequently, there is
a growing body of evidence that supports the need for clinical
studies on the effects of arginine-rich peptides to establish
whether these peptides are equally beneficial in patients with
stroke or other acute and chronic neurological disorders.
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Figure 5: Weight loss at 24 hours after permanent MCAO for
saline (vehicle) and peptide (R18 and TAT-NR2B9c at 100, 300, or
1000 nmol/kg) treatment groups. Values are mean ± SD.

mitochondria and reduce mitochondrial respiration, membrane potential, and levels of reactive oxygen species [49].
It is also interesting to note that Marshall et al. [49] found
that polyarginine peptides taken up by retinal ganglion cells
are localised within small spherical cytoplasmic structures,
which the authors suggested to be mitochondria. Also of
interest are recent studies surrounding the arginine-rich
Borna disease viral mitochondrial-targeting protein, X. The
full-length protein X and X-derived peptide fused to a cell
penetrating peptide display neuronal, axonal, and mitochondrial protective properties [50, 51].
Another mechanism whereby arginine-rich peptides
exert a neuroprotective effect may be related to the ability
of polyarginine and arginine-rich peptides to inhibit the
proteolytic activity of proprotein convertases (e.g., furin and
PC4 [52, 53]), cathepsin C [54], and the proteasome [55, 56],
an effect that may be beneficial following brain ischaemia. For
example, furin is ubiquitously expressed calcium-dependent
convertase responsible for the activation of membrane bound
proteins, including metalloproteinases, which are known to
have adverse effects on the blood brain barrier following
stroke [57]. Similarly, treatments known to inhibit the proteasome which is responsible for the degradation of short-lived
cytosolic proteins are known to reduce brain injury in stroke
[58, 59].
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targeted to the NMDA receptor channel protect neurons from
excitotoxic death,” Nature Biotechnology, vol. 16, no. 3, pp. 286–
291, 1998.
D. J. Mitchell, L. Steinman, D. T. Kim, C. G. Fathman, and J. B.
Rothbard, “Polyarginine enters cells more efficiently than other
polycationic homopolymers,” Journal of Peptide Research, vol.
56, no. 5, pp. 318–325, 2000.
L. Sinai, S. Duffy, and J. C. Roder, “Src inhibition reduces NR2B
surface expression and synaptic plasticity in the amygdala,”
Learning & Memory, vol. 17, no. 8, pp. 364–371, 2010.
Y. Zhang, P. Su, P. Liang et al., “The DREAM protein negatively
regulates the NMDA receptor through interaction with the NR1
subunit,” The Journal of Neuroscience, vol. 30, no. 22, pp. 7575–
7586, 2010.
T. Brustovetsky, J. J. Pellman, X.-F. Yang, R. Khanna, and N.
Brustovetsky, “Collapsin response mediator protein 2 (CRMP2)
interacts with N-methyl-d-aspartate (NMDA) receptor and
Na+ /Ca2+ exchanger and regulates their functional activity,” The
Journal of Biological Chemistry, vol. 289, no. 11, pp. 7470–7482,
2014.
A. Garcı́a-Caballero, V. M. Gadotti, P. Stemkowski et al.,
“The deubiquitinating enzyme USP5 modulates neuropathic
and inflammatory pain by enhancing Cav3.2 channel activity,”
Neuron, vol. 83, no. 5, pp. 1144–1158, 2014.
M. Fotin-Mleczek, S. Welte, O. Mader et al., “Cationic cellpenetrating peptides interfere with TNF signalling by induction
of TNF receptor internalization,” Journal of Cell Science, vol. 118,
no. 15, pp. 3339–3351, 2005.
T. W. Chu, P. M. Grant, and A. W. Strauss, “The role of arginine
residues in the rat mitochondrial malate dehydrogenase transit
peptide,” The Journal of Biological Chemistry, vol. 262, no. 26,
pp. 12806–12811, 1987.
K. Zhao, G.-M. Zhao, D. Wu et al., “Cell-permeable peptide
antioxidants targeted to inner mitochondrial membrane inhibit
mitochondrial swelling, oxidative cell death, and reperfusion
injury,” The Journal of Biological Chemistry, vol. 279, no. 33, pp.
34682–34690, 2004.
K. L. Horton, K. M. Stewart, S. B. Fonseca, Q. Guo, and S.
O. Kelley, “Mitochondria-penetrating peptides,” Chemistry and
Biology, vol. 15, no. 4, pp. 375–382, 2008.
I. Nakase, S. Okumura, S. Katayama et al., “Transformation of
an antimicrobial peptide into a plasma membrane-permeable,
mitochondria-targeted peptide via the substitution of lysine
with arginine,” Chemical Communications, vol. 48, no. 90, pp.
11097–11099, 2012.
M. P. Rigobello, E. Barzon, O. Marin, and A. Bindoli, “Effect of
polycation peptides on mitochondrial permeability transition,”
Biochemical and Biophysical Research Communications, vol. 217,
no. 1, pp. 144–149, 1995.
C. Batandier, B. Guigas, D. Detaille et al., “The ROS production
induced by a reverse-electron flux at respiratory-chain complex
1 is hampered by metformin,” Journal of Bioenergetics and
Biomembranes, vol. 38, no. 1, pp. 33–42, 2006.
B. Guigas, D. Detaille, C. Chauvin et al., “Metformin inhibits
mitochondrial permeability transition and cell death: a pharmacological in vitro study,” Biochemical Journal, vol. 382, no. 3,
pp. 877–884, 2004.

[47] H. H. Szeto, S. Liu, Y. Soong et al., “Mitochondria-targeted
peptide accelerates ATP recovery and reduces ischemic kidney
injury,” Journal of the American Society of Nephrology, vol. 22,
no. 6, pp. 1041–1052, 2011.
[48] A. V. Birk, W. M. Chao, S. Liu, Y. Soong, and H. H. Szeto,
“Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia,” Biochimica et
Biophysica Acta—Bioenergetics, vol. 1847, no. 10, pp. 1075–1084,
2015.
[49] J. Marshall, K. Y. Wong, C. N. Rupasinghe et al., “Inhibition
of N-Methyl-D-aspartate-induced retinal neuronal death by
polyarginine peptides is linked to the attenuation of stressinduced hyperpolarization of the inner mitochondrial membrane potential,” The Journal of Biological Chemistry, vol. 290,
no. 36, pp. 22030–22048, 2015.
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Assessment of dual laser Doppler probe cerebral blood flow recording following
MCAO

In this Chapter, an additional aim in Study 3 was to assess the usefulness of dual laser
Doppler probe recording to identify animals with patent collateral circulation between
cerebral hemispheres, and which may result in smaller or variable infarct volumes.
Consequently, if these animals are able to be identified following MCAO and before
the administration of treatment they could be excluded in future studies, and in doing
so reduce experimental variability in terms of stroke outcomes.

The usefulness of this approach in a transient MCAO stroke model in rats was recently
demonstrated by Cuccione et al. (2016) 1. The procedure involves using one laser
Doppler probe (Probe 1) to detect the cerebral perfusion in the territory of the middle
cerebral artery (MCA) (as per normal), and a second probe (Probe 2) to detect the level
of co-lateral blood flow at the border zone between the anterior cerebral artery (ACA)
and MCA territories. A failure to register a significant perfusion deficit (at least 15%
change from baseline) by Probe 2 after MCAO, is indicative of the presence of
collateral communicating anastomosis between the ACA and the MCA. As the study
in this Chapter was primarily aimed at assessing the usefulness of the information
provided by using a second laser Doppler probe no animals were excluded from the
study, even if Probe 2 registered a drop in cerebral blood flow of at least 15%.

The measurements for the reduction in cerebral blood flow (from baseline) obtained
for the two laser Doppler probes following MCAO are summarised in the linear
regression graphs provided in the Appendix. Measurements were obtained from 42
rats. Linear regression analysis revealed a poor correlation between a reduction in
cerebral blood flow and infarct volume for both probes (Probe 1: R2 = 0.11 and Probe
2: R2 = 0.01).

1

Cuccione, E., Padovano, G., Versace, A., Ferrarese, C., & Beretta, S. (2016).
Cerebral collateral circulation in experimental ischemic stroke. Exp Transl Stroke
Med, 8, 2. doi: 10.1186/s13231-016-0015-0.
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Introduction

Ischaemic stroke occurs when there is a reduced blood supply to a region of the brain,
resulting in neuronal loss and brain injury. Currently, the most effective stroke therapy
is to restore blood flow to the territory of the blocked cerebral artery using tPA
thrombolysis (tissue plasminogen activator) and/or thrombectomy (mechanical
removal of clot). However, to be effective, reperfusion therapies need to be
administered within 4.5 hours after stroke onset, and thus it is estimated that only 515% of eligible stroke patients receive this therapy (Donnan et al., 2008; Henninger
and Fisher, 2016). For the majority of patients with ischaemic stroke there is still no
proven effective therapy to reduce the severity of the stroke and extent of brain injury.

Currently, there are no clinically available neuroprotective therapeutic agents that can
be administered to stroke patients to reduce the severity and extent of brain injury. The
availability of a neuroprotective agent for stroke would provide the potential to reduce
brain injury in patients who do not receive thrombolysis/thrombectomy and further
improve outcomes in those patients who do undergo endovascular recanalisation
therapy. In addition, the early administration of a neuroprotective agent could prolong
neuronal viability within the ischaemic penumbra and thereby also extend the
therapeutic window of thrombolysis/thrombectomy recanalisation therapy. Therefore,
there is an urgent need for the development of new more widely applicable
neuroprotective therapies that can be applied to stroke and other forms of cerebral
ischaemia. Additionally, any treatment that can be applied in the field and/or improve
the safety of thrombolysis /thrombectomy would also be highly advantageous.
Against this backdrop, recent studies in A/Prof Meloni’s laboratory have demonstrated
that poly-arginine and arginine-rich peptides are highly neuroprotective agents for in
vitro injury models that mimic the effect of stroke (i.e. excitotoxicity and oxygen
glucose deprivation), and in the case of poly-arginine-9 (R9), following permanent
MCAO in the rat (Meloni et al., 2014; Meloni et al., 2015ab). These earlier studies
have provided the rationale for this thesis to further investigate poly-arginine peptides
as a neuroprotective therapy for stroke.
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Key findings arising from this thesis

Assessment of poly-arginine peptides and protamine in permanent MCAO stroke
model

The initial aim of this study was to identify a potential lead neuroprotective polyarginine or arginine-rich peptide as a focus for further investigation. Four peptides
were selected for assessment: poly-arginine peptides R12, R15, R18 and the argininerich peptide protamine. Selection of the appropriate poly-arginine peptides was based
on previous in vitro studies, demonstrating that peptide neuroprotective efficacy
increased with increasing arginine polymer length, plateauing at around R15 to R18
(Meloni et al., 2015a). Protamine was selected based on its high neuroprotective
efficacy in vitro, high arginine content (21 arginine residues), its clinical use as a
heparin reversal agent (Van Ryn-McKenna et al., 1990), and its use to slow the
absorption of insulin (Horvath et al., 2007; Mathew et al., 2015). Initial assessment of
the peptides was performed using a permanent MCAO stroke model, since most
ischaemic stroke patients do not receive reperfusion therapy, and as recommended by
the Stroke Treatment Academic Industry Roundtable guidelines (STAIR, 1999).

The permanent MCAO stroke study involved a single peptide dose (1000nmol/kg)
administered 30 minutes after MCAO (Chapters 4 and 7) and revealed neuroprotective
effects for R12, R18 and protamine, whereas R15 did not show any obvious
neuroprotection. Considering that the R15 peptide had previously been shown to have
comparable neuroprotective efficacy to R18 in an in vitro neuronal glutamate
excitotoxicity model (Meloni et al., 2015a), its lack of efficacy in the MCAO model
was surprising. The reason why no observable neuroprotection was obtained for R15
is at present unknown, but it is possible that higher or lower doses of the peptide may
be required to provide a neuroprotective effect. As the R15 result was unexpected, it
would be of interest in future studies to perform additional dose response studies using
a new batch of the peptide in both the permanent and transient MCAO stroke models.
It should be mentioned that the R15 peptide batch used in the initial animal study was
confirmed to be neuroprotective in the in vitro excitotoxicity model (A/Prof Meloni,
personal communication).
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Despite the finding of a lack of efficacy following R15 treatment, the results for R12,
R18 and protamine, which reduced infarct volume by 12.8%, 20.5% and 22.5%
respectively, were in line with a previous study demonstrating that R9 in the same
model, dose and administration time-point, reduced infarct volume by 20% (Meloni et
al., 2015a). Interestingly, the results obtained in the two studies indicate that R9 is
more neuroprotective than R12 despite its shorter polymer length. A possible
explanation for the superior efficacy of the R9 peptide could be due to its likely higher
stability and longer serum half-life, as it was synthesised using D-isoform arginine
residues, which are known to provide greater resistance to proteolytic degradation,
rather than peptides synthesised using the L-isoform (Weinstock et al., 2012).
Therefore, based on the potential superior potency of D-isoform peptides, further
studies in our laboratory are exploring the relative efficacies of D- and L-isoform polyarginine peptides in stroke and other ischaemic brain injury models (e.g. global
cerebral ischaemia, perinatal hypoxia-ischaemia). To this end, recent studies in A/Prof
Meloni’s laboratory using a global cerebral ischaemia model have indicated that R18D
is a more potent neuroprotective agent than R18 (personal communication).

Results from this thesis demonstrated for the first time the neuroprotective properties
of protamine in in vitro and in vivo stroke injury models, and its ability to reduce
glutamic acid induced neuronal intracellular calcium influx (Chapter 7). These
findings are not surprising considering the high arginine content of protamine, and the
previous studies in our laboratory confirming the neuroprotective and calcium influx
inhibitory properties of other arginine-rich and poly-arginine peptides. However,
despite protamine’s neuroprotective properties and its current clinical use, there are
several reasons why it was not selected as a lead neuroprotective peptide. Although
protamine is regarded as a relatively safe drug with a wide therapeutic index, it can be
associated with severe anaphylactic reactions and pulmonary hypotension in a small
proportion of patients who are usually allergic to fish (Horrow, 1985; DeLucia et al.,
1993). Interestingly, it is for these reasons that the poly-arginine peptide R15 has been
evaluated as a safer alternative to protamine as a heparin reversal agent (Byun et al.,
1999; Li et al., 2015). In view of these considerations, and since the neuroprotection
provided by protamine in the permanent MCAO models was not significantly different
to the neuroprotection provided by R18, the latter peptide was therefore selected as the
lead neuroprotective agent. Interestingly, and in line with the known properties of
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protamine, a slight and reversible reduction in blood pressure was observed during the
intravenous administration of the peptide, while a similar effect was not observed for
the other poly-arginine peptides (data not shown).

Neuroprotective dose responsiveness of R18 in permanent MCAO stroke model

Following the initial permanent MCAO study, and the selection of R18 as the lead
peptide, a subsequent study examined the dose responsiveness of R18 at a 60-minute
post-occlusion treatment time point. Importantly, the neuroprotective peptide TATNR2B9c, which is also known as NA-1, was included in the study as a positive control
and benchmark. The NA-1 peptide has undergone rigorous pre-clinical assessment in
rodents and non-human primate stroke models (Table 2 Chapter 2; Cook et al., 2012).
In addition, administration of NA-1 after endovascular aneurysm surgery in humans is
reported to reduce the number, but not volume, of ischaemic lesions (Hill et al., 2012).
As a result of positive outcomes in stroke studies assessing NA-1 neuroprotective
efficacy, two clinical phase III studies of NA-1 in acute ischaemic stroke are either
being planned or underway (ESCAPE-NA1 and FRONTIER; www.strokecenter.org).

The results from this study revealed that R18 reduced infarct volume at the 100, 300
and 1000 nmol/kg doses by 19.7%, 12.0% and 24%, respectively. By contrast, NA-1
had little impact in reducing infarct volume at the doses examined (4.8%, 6.8% and
7.0% for the 100, 300 and 1000 nmol/kg dose, respectively; Chapter 5). In addition,
treatment with the R18 peptide, and to a lesser extent NA-1, resulted in some
functional recovery as assessed by behavioural tests, but not to statistically significant
levels.

These findings further confirmed the neuroprotective properties of R18 and extended
its therapeutic time window to 60 minutes after stroke onset, as well as demonstrating
greater efficacy compared to NA-1 in a severe ischaemic stroke model.

Assessment of arginine-tryptophan peptides in permanent MCAO stroke model

The presence of other amino acids in arginine-containing peptides has been shown to
influence the degree of peptide neuroprotection (Meloni et al., 2015ab). Therefore, the
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primary aim of this study was to identify and assess a potentially more efficacious
arginine-rich peptide, compared to R18, in the permanent MCAO rat stroke model
(Chapter 7).

In order to identify a potentially more effective peptide compared to R18, studies
performed in A/Prof Meloni’s laboratory screened several arginine-rich peptides,
including a cyclic poly-arginine peptide (R12-c), R22 and arginine-tryptophan
containing peptides. The initial aim of the study was to assess whether peptide
cyclisation, further increasing poly-arginine peptide length (i.e. beyond R18), or the
addition of tryptophan residues, would significantly enhance peptide neuroprotective
efficacy in the in vitro excitotoxicity injury model. Despite showing strong
neuroprotective effects, the R12-c and R22 peptides did not appear to be significantly
more efficacious than R18. On the other hand, the addition of tryptophan residues
significantly improved peptide neuroprotective properties. In particular the peptide
R12W8a, composed of 12 arginine and 8 tryptophan residues, displayed the greatest
efficacy, with a potency 10 times higher than R18 in the excitotoxicity model. For this
reason, R12W8a was selected for further assessment in the permanent MCAO rat
stroke model. Likely explanations for the increased neuroprotective potency of
tryptophan containing peptides are provided in the Discussion section of the
manuscript in Chapter 7.

While the R12W8a peptide was highly neuroprotective in vitro, it caused severe
hypotension and cyanotic side effects when administered intravenously at relatively
low doses of 100 and 300 nmol/kg (data not shown). In this regard, it appears its ability
to induce side effects when administered to rats is linked with its increased
neuroprotective potency. It is possible that, based on the potential of R12W8a to
antagonise plasma membrane ion channel receptor levels/function, the cardiac
depressive and vasodilatory effects induced by the peptide are the result of altered
calcium influx and impaired contractility in myocardial and vascular smooth muscle
cells (Horrow, 1985; DeLucia et al., 1993). In addition, it is possible that the cyanosis
is caused by peptide electrostatic interactions with the lung surfactant phospholipid
molecule, phosphatidylglycerol (-1 net charge), leading to increased surface tension of
fluids within alveoli, collapse of alveoli, and consequently a reduced transfer of gases
between the blood and alveolar air.
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Due to the adverse side effects of R12W8a when administered at the 100 and 300
nmol/kg doses, a 30 nmol/kg dose, which did not induce any obvious adverse effects,
was used to assess the in vivo efficacy of the peptide. The study revealed that R12W8a
did not provide any significant neuroprotection following permanent MCAO, unlike
the R18 peptide at the 30 nmol/kg dose, which significantly reduced infarct volume
and cerebral oedema. One explanation for the lack of neuroprotection for R12W8a
when administered in vivo, is that due to its improved endocytic or membrane
traversing properties it is rapidly taken up by vascular tissue (e.g. endothelial cells,
smooth muscle cells) and other organs (e.g. liver, kidney) and thereby severely limiting
its access to the brain.

As a consequence of these findings with R12W8a, it is likely that if this or more potent
arginine-rich peptides are to be developed, a more direct CNS route of delivery (e.g.
intranasal or intracerebral artery) that avoids systemic distribution and potential side
effects of the peptide may need to be considered.

Assessment of R18 in permanent MCAO stroke model, when administered 120 minutes
after stroke onset

Following the positive results obtained for R18 when administered intravenously 60
minutes after permanent MCAO, the treatment administration time point was extended
to 120 minutes (Chapter 8). The rationale for this study was to further investigate the
therapeutic time window for R18 in the permanent MCAO rat model. In contrast to
the previous studies, R18 did not significantly reduce infarct volume when
administered 120 minutes after stroke onset at the dose of 1000 nmol/kg. Interestingly
however, R18 significantly reduced severity of cerebral oedema (by 21%) and
improved some behavioural outcomes, specifically neurological assessment score and
rota-rod performance.

These findings suggest that while R18 has a limited ability to reduce infarct volume
when administered 120 minutes after stroke onset in the permanent MCAO model used
in this study, it still has the capacity to reduce other damaging effects of stroke.
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Neuroprotective dose responsiveness of R18 in transient MCAO stroke model

An additional aim of this project was to assess the efficacy of R18 in a stroke model
incorporating reperfusion-induced damage. Animal stroke models that incorporate
cerebral reperfusion are particularly relevant in the clinical setting due to tPA
thrombolysis therapy and more recently the application of thrombectomy for
ischaemic stroke. While successful recanalisation and reperfusion provides the best
opportunity to salvage vulnerable brain tissue following stroke, it can also contribute
to brain injury through several different mechanisms (Warach and Latour, 2004;
Kalogeris et al., 2012). For example, reperfusion of previously ischaemic cerebral
tissue can damage vascular endothelium, cause excessive production of reactive
oxygen species and stimulate the production of inflammatory cytokines (Warach and
Latour, 2004; Kalogeris et al., 2012). These damaging processes, in addition to
increasing neuronal death, can promote the formation of cerebral oedema and in severe
cases may result in haemorrhagic transformation or intracerebral haemorrhage,
characteristically occurring 24 to 36 hours after stroke (Khatri et al., 2007).

Similar to the permanent MCAO study, R18 dose-dependently reduced infarct volume.
For example, at the 30, 100, 300 and 1000 nmol/kg doses, R18 reduced infarct volume
by 9.6%, 12.2%, 24.8% and 35.1% respectively. The NA-1 peptide, which was also
used as a positive control in the study, was less effective and reduced lesion volume
by 7.0%, 16.5%, 16.6% and 26.1% respectively, for the corresponding doses. In
addition, R18 significantly reduced cerebral oedema at three doses (100, 300 and 1000
nmol/kg), while NA-1 only significantly reduced swelling at the highest dose of 1000
nmol/kg (Chapter 6). Several of the R18 and NA-1 treatment groups also showed
statistically significant improvement in at least one functional parameter of the
adhesive tape test, and a positive trend in the neurological assessment and rota-rod.

Taken together, the results of the study confirm that R18 is effective at reducing brain
injury and cerebral oedema, and improving functional outcomes in a stroke model that
is associated with reperfusion-induced damage. Moreover, as demonstrated in the
permanent MCAO stroke model, R18 appeared to be more effective than the NA-1.
The effectiveness of R18, in a stroke model associated with cerebral reperfusion, is
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evidence that the peptide has the potential to further improve outcomes in stroke
patients undergoing endovascular recanalisation therapies.

Interestingly, both R18 and NA-1 treated animals displayed some positive behavioural
improvement when treated at the lowest doses (30 nmol/kg), even when infarct volume
was not significantly reduced. This result suggests that at low concentration the
peptides may have a positive effect on synaptic connectivity and/or plasticity that
improves function, as has been recently demonstrated for the closely related NA-1
peptide TAT-HA-NR2B9c (Zhou et al., 2015).

Assessment of R18 in the transient MCAO stroke model, when administered 120
minutes after stroke onset

Following the positive results with R18 in the transient MCAO stroke model, efficacy
of the peptide was assessed when administered at a later time point (120 minutes) and
following a longer duration of MCAO (180 minutes) (Chapter 8). The study revealed
that R18 when administered at the 1000 nmol/kg dose did not significantly reduce
infarct volume. Similarly, the NA-1 also did not reduce infarct volume. However, R18
treatment was associated with a reduction in cerebral oedema and a significant
improvement in time to remove the adhesive tape from the left paw.

Intra-arterial R18 treatment at time of reperfusion in transient MCAO stroke model

A final aim of this thesis was to assess the effectiveness of R18 when administered
intra-arterially immediately after reperfusion in the transient MCAO stroke model
(Chapter 8). The intra-arterial administration of a neuroprotective agent has recently
become clinically relevant with the application of endovascular catheters used during
mechanical thrombectomy. This study used a transient MCAO model consisting of a
120-minute occlusion period, administration of peptide immediately following
reperfusion (i.e retraction of the intraluminal suture), and a reduced peptide dose (100
nmol/kg). Results revealed that neither R18 nor the NA-1 significantly reduced infarct
volume, although a modest positive trend was observed. As in previous studies, R18
reduced cerebral oedema. In addition, R18 and to a lesser extent NA-1 treated animals,
displayed improvements in some functional outcomes.
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Significance of lack of efficacy of delayed (120 minutes) post-stroke treatment with
R18 and NA-1 after permanent and transient MCAO

The inability of R18 and NA-1 to significantly reduce infarct volume when
administered 120 minutes after permanent or transient MCAO in rats, does not
necessarily indicate that the peptide will be ineffective when administered at the same
time point after stroke onset in humans. However, when attempting to extrapolate the
results in the rat models to humans, differences in metabolism, physiology and
anatomy between the two species need to be taken into consideration. For example, in
the setting of stroke, there is evidence that brain infarct development occurs more
rapidly in rats than in humans (Saita et al., 2004; Andreollo et al., 2012; Sengupta,
2013). However, of even more relevance is knowledge of the extent of potentially
salvageable penumbral tissue after stroke and at the time of treatment administration.

While not extensively studied, available evidence suggests infarct volume
development in rats following stroke is animal strain and model dependent. In a study
by Wetterling et al. (2016), it was demonstrated that in rats subjected to a transient
MCAO the presence of penumbral tissue, before incorporation into the core, can vary
from between 1 and 6 hours. In studies using permanent MCAO in rats, Bratane et al.
(2011) showed the presence of penumbral tissue up to 2-hours after occlusion, while
McCabe et al. (2009) reported the absence of penumbral tissue by 60 minutes after
stroke onset.

In addition, the negative results obtained with NA-1 when administered at 2-hours
after stroke onset are in line with other studies in stroke models using rodents when
the peptide is administered more than 60 minutes after MCAO. For example, NA-1
failed to show neuroprotective effects when administered intravenously after 120
minutes from stroke onset in a permanent MCAO (Soriano et al., 2008; Kleinschnitz
et al., 2016).

Therefore, the inability of R18 and NA-1 peptides to reduce infarct volume when
administered 2 hour post-stroke, after permanent and transient MCAO, may simply
reflect the lack of potentially salvageable penumbral tissue. In support of this, and
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considering the similarities between non-human primates and humans, a previous
study by Cook et al., (2012) demonstrated neuroprotective efficacy of NA-1 when
administered 3 hours after stroke onset in macaques subjected to a 3.5-hour MCAO.

Cerebral collateral circulation and infarct volume variability

Experimental variability in animal stroke models is a well-known limitation for
preclinical stroke studies (Coyle and Jokelainen, 1982; Cuccione et al., 2016). In this
instance, the presence of collateral/accessory circulations between the main cerebral
vessels may affect the degree of brain injury by providing additional blood supply to
the ischaemic area during MCAO, and thereby resulting in smaller or variable infarct
volumes.

In an attempt to identify animals that may return a small infarct volume due to good
collateral cerebral circulation following MCAO, during the last animal study (Chapter
8) two laser Doppler probes were utilised to measure cerebral blood. Cuccione et al.
(2016) demonstrated the usefulness of this approach to identify animals with good
collateral circulation following transient MCAO in rats. The procedure involves using
one laser Doppler probe to detect the cerebral perfusion in the territory of the middle
cerebral artery (MCA), and a second probe to detect the level of collateral blood flow
at the border zone between the anterior cerebral artery (ACA) and MCA territories. A
failure to register a significant perfusion deficit (at least 15% change from baseline)
by the second probe after MCAO is indicative of the presence of collateral
communicating anastomosis between the ACA and the MCA. However, in this study
the results did not reveal any obvious correlation in a drop in cerebral blood flow
registered by the second probe and associated infarct volumes (Chapter 8; Appendix).

While the exact reason for the discrepancy between the present findings obtained and
those reported by Cuccione et al. (2016) are not known, improving experimental
consistency and finding additional tools to exclude animals that are likely to generate
a smaller than anticipated infarct volume following MCAO, remains an important
objective in future studies.
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Limitations of present study

While the results from this study provide strong evidence for the neuroprotective
properties of poly-arginine and arginine-rich peptides in rat MCAO stroke models, the
limitations of these studies need to be acknowledged.

It is likely that some aspects of the experimental design of the animal studies such as
stroke severity, the high variability associated with behavioural outcomes after stroke,
and the acute 24 hour endpoint, coupled with the relatively small animal numbers,
explain why improvements in functional outcomes were modest and often did not
reach statistical significance. Therefore, to overcome these limitations and provide
further confirmation of the ability of arginine-rich peptides to improve functional
outcomes, additional studies with extended experimental end-points and a larger
number of animals, are required. It may also be useful to assess the peptides in animal
stroke models that are more amenable for the assessment of functional outcomes
following stroke (e.g Endothelin-1 stroke model; Soleman et al., 2010). In addition,
extended experimental end-points would also confirm whether the histological
neuroprotection provided by arginine-rich peptides is maintained long-term.

This thesis only studied the neuroprotective effects of the peptides in one species of
animal (Sprague Dawley rats) and in healthy adult males, while additional factors like
age and the presence of comorbidities (e.g. hypertension, diabetes, obesity) were not
investigated. Age and comorbidities are particularly relevant to stroke, as increased
age and the presence of comorbidities are risk factors for stroke. It is also
recommended (STAIR) that studies are performed in different strains of animal of the
same species, as genetic differences between strains can influence the infarct size
(Braeuninger and Kleinschnitz, 2009). In addition, following positive results in rodent
stroke models, assessment of neuroprotective agents should be tested in higher-order
gyrencephalic species (e.g. dogs, sheep, pigs, non-human primates) with a brain and
neuro-cortical pathways more similar to humans. It is also important that positive
results can be replicated in at least one other independent laboratory (Fisher et al.,
2009).
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In future studies it would also be useful to assess the time course of ischaemic tissue
progression in the stroke models used, in particular in relation to the time of treatment
administration and extent of potential salvageable penumbral tissue. This could be
achieved with the use of MRI (Magnetic Resonance Imaging), as has been
demonstrated previously in animal studies (McCabe et al., 2009; Bratane et al., 2011;
Wetterling et al., 2016).

Therefore, while the present study has undertaken the initial steps in the
neuroprotective assessment of a poly-arginine peptide, namely R18, it is clear that
additional studies as recommended for stroke therapeutics (STAIR) are now required.

Summary of important findings of study and future directions

The findings presented in this thesis have further confirmed the neuroprotective
properties of poly-arginine peptides (R12 and R18) and an arginine-rich peptide
(protamine) following MCAO stroke in the rat. Although additional studies are
required, as outlined above, to evaluate more fully the potential of R18 as a
neuroprotective therapy in stroke, it would appear that arginine-rich peptides represent
a promising new class of neuroprotective agent that warrants further evaluation in
other animal models.
Importantly, concomitant studies conducted in A/Prof Meloni’s laboratory are also
showing neuroprotective efficacy for R18 in global cerebral ischaemia and neonatal
hypoxia ischaemic models (data not shown). Therefore, based on the results obtained
in this thesis, and other ongoing studies in our laboratory and others (Meloni et al.,
2015b; Marshall et al 2015), it would appear that arginine-rich peptides have great
potential as a treatment for stroke and other forms of acute brain injury, and possibly
even for chronic neurological disorders.
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Figure A1. Linear regression analysis between infarct volume and cerebral
blood flow deficit after MCAO, as detected by laser Doppler Probe 1 and 2.

